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Abstract 
Introduction and Aim  
Most acute Hepatitis C virus (HCV) infections become chronic, with some progression to 
liver cirrhosis or hepatocellular carcinoma (HCC). Current therapy against chronic HCV 
infection includes pegylated interferon (PEG-IFN)-α, which achieves a sustained virological 
response in only 50% of patients. IFN-α induces JAK/STAT activation and subsequent antiviral 
genes (IFN-stimulated genes, ISG) expression. Clinically, hepatic ISG expression is known to 
be associated with the efficacy of IFN therapy. Recently, a genome-wide association study 
showed that single nucleotide polymorphisms (SNPs), located near interleukin (IL)28B, are 
strongly associated with a virological response to IFN therapy. IL28B SNP was reported to 
associate with ISGs expression, although, the mechanism underlying the association was 
unclear. 
The main causes of low response by IFN therapy may be (i) low compliance with the 
therapy, which must be administered subcutaneously, costs and the side effects of IFN, and (ii) 
poor prediction of clinical outcomes with IFN therapy. To overcome these problems, an orally 
available small molecule IFN would be valuable, and association between IL28B SNP and ISG 
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expressions is elucidated. 
Methods  
Chapter 1: Using HCV replicon harboring cells, a high-throughput screening was 
performed to identify HCV inhibitors. The induction of gene expression, especially ISGs, and 
JAK/STAT phosphorylation by RO8191 treatment in the replicon cells were detected. RO8191 
activity in the cells that were knocked down IFN signaling molecules was evaluated. RO8191 
activity in IFN receptor-deficient cells was also analyzed. I administered orally RO8191 to mice 
and detected gene expression in the mice liver. I also administered RO8191 to HCV infected 
humanized liver chimeric mice and measured HCV viral titer. 
Chapter 2: Data were collected from 74 patients with HCV-induced hepatocellular 
carcinoma. The IL28B genotype and hepatic ISG mRNA levels were analyzed to clarify their 
association, focusing on the progression of liver fibrosis. 
Results  
Chapter 1: I identified an orally available, small-molecule type I IFN receptor agonist 
(RO8191) that directly transduces the IFN signal cascade and stimulates antiviral gene 
expression. Like type I IFN, the small-molecule compound induces ISG expression for antiviral 
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activity in vitro and in vivo in mice, and the ISG induction mechanism is attributed to a direct 
interaction between the compound and IFN-α receptor 2, a key molecule of IFN-signaling on 
the cell surface. 
Chapter 2: Hepatic ISG15 expression was lower in the IL28B major (rs8099917 TT) group 
than that in the IL28B minor (rs8099917 TG or GG) group. IFN γ-induced protein-10 (IP-10) 
expression was similar between the IL28B major and minor groups. IP-10 expression was 
elevated with advancing stages of liver fibrosis in HCV-infected patients. In patients with mild 
or no fibrosis, the IL28B major group had lower IP-10 expression than the IL28B minor group. 
However, in patients with advanced fibrosis, IP-10 expression was not different between the 
IL28B major and minor groups. 
Conclusions  
RO8191 is a novel small molecule that activates IFN signaling directly, and the host 
response to hepatitis C virus infection, focusing on the association among IL28B SNP, IP-10 
expression, other ISG expression and liver fibrosis, is analyzed.  
RO8191 would contribute a development of novel treatment to chronic hepatitis C patients 
even with IL28B unfavorable genotype.   
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Abbreviations 
γ-GTP, γ-glutamyl transpeptidase 
ALT, alanine aminotransferase 
ANOVA, Analysis of variance 
BMI, body mass index 
DAB, 3,3’ -diaminobenzidine tetrahydrochloride 
DMEM, Dulbecco’s modified Eagle’s medium 
ECD, Extracellular domain 
EMCV, Encephalomyocarditis virus 
FBS, Fetal bovine serum 
FCS, Fetal calf serum 
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase 
HCC, Hepatocellular carcinoma 
HCV, Hepatitis C virus 
HTS, High-throughput screening 
KO, Knockout 
IC50, 50% inhibitory concentration 
IFN, Interferon 
IFNAR, IFN-α receptor 
IL, Interleukin 
IP-10, IFN γ-induced protein-10 
ISG, IFN-stimulated genes 
ISGF3, IFN-stimulating gene factor 3 
ISRE, IFN-stimulated response element 
MEF, Mouse embryonic fibroblasts 
NBNC, Non-B, non-C 
NEAA, Non essential amino acid 
NS, Nonstructural 
PEG, Pegylated 
RBV, Ribavirin 
RT-PCR, Reverse transcription-polymerase chain reaction 
SCID, Severe combined immunodeficient  
SNP, Single nucleotide polymorphisms 
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SP, Sodium pyruvate 
SPR, Surface plasmon resonance 
STAT, Signal transducers and activators of transcription 
SVR, Sustained virological response 
TLR, Toll-like receptor 
TNF, Tumor necrosis factor 
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General Introduction 
Hepatitis C virus (HCV) infection affects 170 million people worldwide [41], and most 
acute HCV infections become chronic, with some progression to liver cirrhosis or 
hepatocellular carcinoma (HCC). HCV has a plus-strand RNA genome that encodes both 
structural proteins and the nonstructural (NS) proteins 2, 3, 4A, 4B, 5A and 5B. HCV infection 
induces Interferon (IFN) production via innate immune cascades [47, 65]. IFN consists of type I 
(IFN-α, β, and others), II (only IFN-γ), and III (IFN-λs; interleukin, or IL28A/B and IL29) IFNs. 
IFNs induce the expression of a subset of IFN-stimulated genes (ISG) [71, 72], some of which 
show antiviral activity or are involved in lipid metabolism, apoptosis, protein degradation and 
inflammation [10]. Broadly speaking, type I IFNs bind to their receptor, causing the 
phosphorylation and activation of JAK1 and Tyk2, which is followed by the phosphorylation of 
signal transducers and activators of transcription (STATs) and subsequent ISG expression. To 
activate the JAK/STAT pathway, IFN-α requires the IFN-α/β receptor, which consists of 2 
subunits, IFN-α receptor (IFNAR) 1 and IFNAR2. These IFNAR subunits together form a 
heterodimer upon IFN stimulation. This association of IFNAR2 and IFNAR1 is required to 
mediate the antiviral, antiproliferative, and apoptotic effects of type I IFNs [53, 58, 80], because 
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the dimerization of IFNARs induces the phosphorylation of the receptor-associated tyrosine 
kinases, JAK1 and Tyk2, and the phosphorylated JAK kinases then phosphorylate STAT1 and 
STAT2. In turn, phosphorylated STAT1 and STAT2 bind to IRF9 to form the transcriptional 
activator IFN-stimulating gene factor 3 (ISGF3) that induces the expression of a subset of ISGs.  
Current standard therapy against chronic HCV infection includes the use of host 
factor-targeting pegylated (PEG) IFN-α and ribavirin (RBV) [19], which achieve a sustained 
virological response (SVR) in only 50% of patients chronically infected with the HCV genotype 
1 [17, 50, 85]. The main causes of this low rate of efficacy may be (i) low compliance with the 
therapy, which must be administered subcutaneously, and (ii) poor prediction of clinical 
outcomes with IFN therapy.  
Regarding the lack of compliance, the current therapy using recombinant IFN is a weekly 
injectable formulation that is unstable, requires refrigeration, and is expensive and complex to 
administer. Furthermore, therapy is often poorly tolerated as a result of the presence of many 
adverse effects, including flu-like symptoms, hematological abnormalities and adverse 
neuropsychiatric events, any of which may require early discontinuation [7]. These side effects 
may result in dose modifications that lead to less-than-optimal responses. Recent trends in drug 
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development focus on drugs targeted against viral proteins such as NS 3/4A serine protease, 
RNA helicase, NS4B, NS5A, and NS5B RNA-dependent RNA polymerase [83]. Adding such 
an inhibitor to the standard therapy achieved significantly higher SVR rates, but the issue still 
remains that using these inhibitors without injectable IFN possibly yields clinical resistance [38]. 
To overcome this problem and alleviate the low compliance outlined above, an orally available 
IFN would be valuable because the dosing regimen is less complex. Using quantitative 
high-throughput screening (HTS), I identified in this study a novel small molecule that acts like 
IFN by directly interacting with the type I IFN receptor to drive ISG expression. My results 
indicate that oral administration of the small-molecule IFN agonist stimulates ISG expression in 
mice, and that the ISG expression from this small-molecule IFN provides antiviral activity, 
indicating that the compound may be a potential therapeutic IFN substitute [35]. 
Regarding the latter cause, the host factors that are important in the early response to 
therapy remain unknown, although several studies that showed an association between ISG 
expression and clinical outcomes with IFN have been conducted [26]. Hepatic ISG expression is 
known to be associated with the efficacy of IFN therapy, and high ISG expression is a 
predictive factor for a poor IFN response. Recently, a genome-wide association study showed 
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that single nucleotide polymorphisms (SNPs), located near IL28B, which encodes for IFN-λ3, 
are strongly associated with a virological response to IFN therapy and spontaneous clearance of 
HCV [18, 63, 74, 76, 77]. Especially in Japanese patients, rs8099917 is closely associated with 
efficacy for IFN therapy; patients with the TT genotype (termed IL28B major) have a stronger 
response to IFN therapy than those with TG or GG genotypes (termed IL28B minor) [76]. Even 
after liver resection because of HCC [32] or liver transplantation [16], the efficacy of therapy is 
associated with IL28B SNP. More recently, IL28B major patients were reported to express 
hepatic ISGs, which were lower than those in IL28B minor patients [13, 26]. However, after 
liver resection for HCC, the association between hepatic ISG expression and the efficacy of 
therapy is still unclear. IFN γ-induced protein-10 (IP-10) expression is also a predictor for IFN 
therapy, and high IP-10 expression is a predictive factor for a poor IFN response [39, 64]. 
Unlike other ISGs, serum IP-10 protein levels have been reported to be associated with 
differences in IL28B SNP [15, 40], and they also have been found not to be associated with 
differences in IL28B SNP [8]. IP-10 is one of the ISGs, and it is regulated by inflammatory 
cytokines, such as tumor necrosis factor (TNF)-α, via NF-κB transcription factor [54]. TNF-α is 
elevated in severe fibrosis patients [2]; therefore, IP-10 expression should be elevated in 
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response to progression of liver fibrosis. 
To clarify why IP-10 expression is not correlated with IL28B SNP, I genotyped IL28B 
SNP and quantitated the hepatic ISGs. I then analyzed their association, focusing on the 
progression of liver fibrosis. I found that IP-10 expression is associated with IL28B SNPs only 
in patients with mild or no fibrosis [36]. 
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1-1. Abstract 
Most acute HCV infections become chronic and some progress to liver cirrhosis or 
hepatocellular carcinoma. Standard therapy involves an IFN-α-based regimen, and efficacy of 
therapy has been significantly improved by the development of protease inhibitors. However, 
several issues remain concerning the injectable form and the side effects of IFN. Here, I report 
an orally available, small-molecule type I IFN receptor agonist that directly transduces the IFN 
signal cascade and stimulates antiviral gene expression. Like type I IFN, the small-molecule 
compound induces ISG expression for antiviral activity in vitro and in vivo in mice, and the ISG 
induction mechanism is attributed to a direct interaction between the compound and IFN-α 
receptor 2, a key molecule of IFN-signaling on the cell surface. My study highlights the 
importance of an orally active IFN-like agent, both as a therapy for antiviral infections and as a 
potential IFN substitute. 
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1-2. Introduction 
HCV infection affects 170 million people worldwide [41], and most acute HCV infections 
become chronic, with some progression to liver cirrhosis or hepatocellular carcinoma. HCV has 
a plus-strand RNA genome that encodes both structural proteins and the NS proteins 2, 3, 4A, 
4B, 5A and 5B. Current standard therapy against chronic HCV infection includes the use of host 
factor-targeting PEG-IFN-α and RBV [19], which is effective in only 50% of patients 
chronically infected with HCV genotype 1 [85]. The main causes of this low rate of efficacy 
may be (i) SNPs in the upstream region of the IL28B gene and (ii) low compliance with the 
therapy, which must be administered subcutaneously. Regarding the first cause—SNPs—the 
host factors that are important in the early response to therapy remain unknown. However, 
recent studies report that genetic variants near IL28B, which encodes IFN-λ3 (interleukin 28B), 
correlate with the response to treatment of chronic hepatitis C infection using IFN-α/RBV 
combination therapy [18, 74, 76, 77]. Patients with an rs12979860 SNP genotype of CC are 
reported to have a stronger response to IFN therapy (up to an 80% SVR rate with the combined 
therapy) than those with TC or TT genotypes [18]. Regarding the lack of compliance, the 
current therapy using recombinant IFN is a weekly injectable formulation that is unstable, 
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requires refrigeration, and is expensive and complex to administer. Furthermore, therapy is 
often poorly tolerated as a result of the presence of many adverse effects, including flu-like 
symptoms, hematological abnormalities and adverse neuropsychiatric events, any of which may 
require early discontinuation [7]. These side effects may result in dose modifications that lead to 
less-than-optimal responses. 
Recent trends in drug development focus on drugs targeted against viral proteins such as 
NS 3/4A serine protease, RNA helicase, NS4B, NS5A, and NS5B RNA-dependent RNA 
polymerase [83]. Very recently, two NS3/4A protease inhibitors, telaprevir and boceprevir, have 
been approved as new anti-HCV agents. Adding such an inhibitor to the standard therapy 
achieved significantly higher SVR rates, but the issue still remains that using these inhibitors 
without injectable IFN possibly yields clinical resistance [38]. To overcome this problem and 
alleviate the low compliance outlined above, an orally available IFN would be valuable because 
the dosing regimen is less complex. 
IFNs induce the expression of a subset of ISG [71], some of which show antiviral activity 
or are involved in lipid metabolism, apoptosis, protein degradation and inflammation [10]. IFNs 
are not only effective against HCV infection, but are also essential for innate immunity. Broadly 
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speaking, type I IFNs (IFN-α and -β) bind to their receptor, causing the phosphorylation and 
activation of JAK1 and Tyk2, which is followed by the phosphorylation of STATs and 
subsequent ISG expression. To activate the JAK/STAT pathway, IFN-α requires the IFN-α/β 
receptor, which consists of 2 subunits, IFNAR1 and IFNAR2. These IFNAR subunits together 
form a heterodimer upon IFN stimulation. This association of IFNAR2 and IFNAR1 is required 
to mediate the antiviral, antiproliferative, and apoptotic effects of type I IFNs [53, 58, 80] 
because the dimerization of IFNARs induces the phosphorylation of the receptor-associated 
tyrosine kinases, JAK1 and Tyk2, and the phosphorylated JAK kinases then phosphorylate 
STAT1 and STAT2. In turn, phosphorylated STAT1 and STAT2 bind to IRF9 to form the 
transcriptional activator ISGF3 that induces the expression of a subset of ISGs [71]. 
Using quantitative HTS, I identified in this study a novel small molecule that acts like IFN 
by directly interacting with the type I IFN receptor to drive ISG expression. My results indicate 
that oral administration of the small-molecule IFN agonist stimulates ISG expression in mice, 
and that the ISG expression from this small-molecule IFN provides antiviral activity, indicating 
that the compound may be a potential therapeutic IFN substitute. 
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1-3. Materials and Methods 
Cell culture, mice, and reagents 
The #Huh7/3-1 cell line, which expresses HCV replicons, was kindly presented from F. 
Hoffmann-La Roche (Basel, Switzerland). The cells were cultured in 0.5 mg/mL 
G418-containing Dulbecco’s modified Eagle’s medium (DMEM, GIBCO, Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS, HyClone, Logan, UT). The replicon construct 
was derived from pFK-I377neo/NS3-3ʹ/WT, as previously reported [66]. Hc cells (DS Pharma 
Biomedical, Tokyo, Japan) were cultured in CSC Complete Defined Serum-Free Medium (Cell 
Systems Corporation, Kirkland, WA) supplemented with SF4ZR-500-D Rocket Fuel. Toll-like 
receptor (Tlr) knockout (KO) mouse embryonic fibroblasts (MEFs) were purchased from 
OrientalBioService, Inc. (Kyoto, Japan), Ifnar1 KO MEF was kindly gifted by Prof. Takaoka. 
2fTGH, and U1A and U5A cells were kindly gifted by Prof. Stark. Culture conditions for the 
other cell lines are shown in Table 1. Six-week-old C57BL/6J mice were obtained from Charles 
River Laboratories (Yokohama, Japan). Chimeric mice harboring a functional human liver cell 
xenograft were purchased from PhoenixBio (Hiroshima, Japan). The protocol was reviewed by 
the Institutional Animal Care and Use Committee of Chugai Pharmaceutical Co., Ltd. and all 
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mouse experiments were performed in accordance with the Guidelines for the Accommodation 
and Care of Laboratory Animals promulgated in Chugai Pharmaceutical Co., Ltd. Recombinant 
human IFN-α2a was a kind gift from F. Hoffmann-La Roche. Recombinant murine IFN-αA and 
human IFN-β1a were purchased from PBL Interferon Source. Recombinant TNF-α and IFN-γ 
were purchased from R & D Systems (Minneapolis, MN). Imiquimod was purchased from LKT 
Laboratories (St. Paul, MN). JAK inhibitor I was purchased from Merck (Darmstadt, Germany). 
 
Luciferase assay 
Luciferase activity was quantified using the Steady-Glo Luciferase assay system (Promega, 
Madison, WI) and the EnVision 2013 Multilabel Reader (PerkinElmer, Waltham, MA). 
 
WST-8 assay 
The viability of drug-treated Huh-7 cells was determined using a WST-8 cell counting kit 
(Dojin Laboratories, Tokyo, Japan). 
 
Real-time reverse transcription-polymerase chain reaction (RT-PCR) 
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Total RNA was extracted using RNeasy (Qiagen, Venlo, Netherlands), and cDNA was 
synthesized using a Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, 
Indianapolis, IN). Gene expression was measured using the LightCycler 480 System and 
LightCycler 480 Probes Master (Roche Applied Science). The amplification used 95 °C for 5 
min., followed by 50 cycles of: 95 °C for 10 sec., and 60 °C for 30 sec. Human β-actin or rodent 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Applied Biosystems, Foster City, CA) 
expression was used as the endogenous reference for each sample. Primers and TaqMan probes 
for genes were designed using the Universal Probe Library Assay Design Center (Roche 
Applied Science; Table 2). The probes used were from the Roche Universal Probe Library 
(Roche Applied Science). The samples were run in triplicate for each target gene, and each 
reference gene was used as an internal control. 
 
Western blotting and immunostaining 
Cells were lysed in CelLytic M Cell Lysis Reagent (Sigma-Aldrich St. Louis, MO) 
containing Protease Inhibitor Cocktail (Sigma-Aldrich,) and PhosSTOP (Roche Applied 
Science). Rabbit polyclonal antibodies against STAT1, STAT3, STAT6, pY701-STAT1, 
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pY690-STAT2, pY705-STAT3, pS727-STAT3, pY694-STAT5, pY641-STAT6, 
pY1022/1023-JAK1, and pY1054/1055-Tyk2 were purchased from Cell Signaling Technology 
(Danvers, MA). Rabbit polyclonal antibodies against actin, STAT2 and STAT5 were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Tyk2 rabbit polyclonal antibody was 
purchased from Upstate. Anti-IFNAR1 mouse monoclonal (MAB245) and anti-IFNAR2 sheep 
polyclonal antibodies were purchased from R & D Systems. Anti-NS3, anti-NS5A, and 
anti-NS5B rabbit polyclonal antibodies were a kind gift from F. Hoffmann-La Roche. 
Anti-NS4A and anti-NS4B mouse monoclonal antibodies were kindly gifted from the Tokyo 
Metropolitan Institute of Medical Science. Proteins were detected using the Odyssey Infrared 
Imaging System (LI-COR, Lincoln, NE). For immunostaining analysis, the cells were fixed on a 
35-mm glass-based dish (Iwaki, Tokyo, Japan) with 4% paraformaldehyde, blocked using 5% 
fetal bovine serum in phosphate-buffered saline, and then incubated with anti-NS3 and 
anti-NS4A antibodies. The cells were then washed and incubated with Alexa488-labeled 
anti-rabbit IgG and Alexa568-labeled anti-mouse IgG (Molecular Probes, Eugene, OR) and 
analyzed using confocal laser microscopy. 
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JFH-1 antiviral assay 
A cured K4 cell line derived from HuH-7 HCV replicon cells was maintained in DMEM 
supplemented with 10% fetal calf serum (FCS), high-glucose nonessential amino acids, and 
HEPES (Invitrogen, Carlsbad, CA). The JFH-1/K4 cell line, which was persistently infected 
with the HCV JFH-1 strain, was maintained under the same conditions as the cured K4 cell line. 
For the anti-HCV assay of JFH-1/K4 cells persistently infected with the JFH-1 strain, JFH-1/K4 
cells were seeded in a 24-well tissue culture plate containing DMEM supplemented with 10% 
FCS, high-glucose nonessential amino acids, and HEPES (Invitrogen). After overnight 
incubation, serial dilutions of reagent in growth medium were added. After 72 h, total RNA was 
purified from the JFH-1/K4 cells using Isogene (Nippon Gene, Tokyo, Japan). HCV-RNA was 
quantified by real-time PCR as previously reported [75]. 
 
Encephalomyocarditis virus (EMCV) cytopathic effect assay 
This assay was performed on A549 cells seeded in a 96-well tissue culture plate containing 
DMEM supplemented with 10% FBS. After overnight incubation, the indicated concentrations 
of each reagent were added to the growth medium. After 12 h, 100 TCID50/mL EMCV was 
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added, and after another 48 h, viable cells were stained with 0.5% crystal violet. RNAi 
experiment using EMCV was also performed on A549 cells seeded in a 96-well tissue culture 
plate containing DMEM supplemented with 10% FBS. I transfected STAT1- or STAT2-siRNA 
to A549 cells, and after 72 h, I infected EMCV to the cells and treated them with 1 µM RO8191 
or 2 IU/mL IFN. After additional 48 h incubation, I evaluated the cell viability by staining with 
crystal violet. 
 
GeneChip and data analysis 
Total RNA was extracted from 107 HCV replicon cells cultured for 8 h in the presence of 2 
µM RO8191 or 4 IU/mL IFN-α with TRIzol Reagent (Invitrogen). Reverse transcription, RNA 
labeling (5 µg of total RNA), hybridization to Human Genome U133 Plus 2.0 Arrays 
(Affymetrix, Santa Clara, CA), and scanning were performed according to the manufacturer’s 
instructions (Affymetrix, http://www.affymetrix.com). GC-RMA (GeneChip Robust Microarray 
Analysis) algorithms were used to generate scaled gene expression values. The fold change 
compared to untreated cells was calculated, and probe sets were selected for genes that were at 
least 2.0-fold upregulated in RO8191- and IFN-α-treated cells relative to the control cells. 
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RNA interference 
For all double-stranded RNAs, ON-TARGET Plus siRNA reagents (Dharmacon, Lafayette, 
CA) were used (Table 3). The siRNAs were transiently transfected using Lipofectamine 
RNAiMAX Transfection reagent (Invitrogen) according to the manufacturer’s protocols for 
reverse transfection. 
 
Plasmids and transfection 
IFN-stimulated response element (ISRE) and NF-κB reporter gene were purchased from 
Clontech (Mountain View, CA). IFNAR2 was cloned into a pCOS2 vector harboring the EF1α 
promoter. Plasmids were transfected using FuGENE HD (Roche Applied Science) according to 
the manufacturer’s instructions. 
 
Surface plasmon resonance (SPR) measurements 
SPR binding studies were performed using a Biacore T100. Recombinant IFNAR2 
extracellular domain (ECD) protein was purchased from R & D Systems. The protein (1 
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mg/mL) was diluted 1:20 with 10 mM sodium acetate buffer (pH 5.0) and mixed with 2 µM 
RO8191 for stabilization of the binding site. The mixture was immobilized on a Series S sensor 
chip CM7 using amine coupling. RO8191 and PEG-IFN-α2a (Chugai Pharmaceutical, Tokyo, 
Japan) were injected onto the sensor chip at a flow rate of 0.03 mL/min. Response curves were 
generated by subtraction of the background signal generated simultaneously on a control flow 
cell. Kinetic parameters were obtained by global fitting of the sensorgrams to a 1:1 model using 
Biacore T100 Evaluation Software, version 2.0.1. 
 
Humanized liver mice study 
The chimeric mice were generated by transplanting human primary hepatocytes into severe 
combined immunodeficient (SCID) mice carrying the urokinase plasminogen activator 
transgene controlled by an albumin promoter [49]. The chimeric mice used in this study were 
applied from Inoue et al. [29], and had a high substitution rate of human hepatocytes. Six weeks 
after hepatocyte transplantation, patient serum containing 106 copies of HCV genotype 1b was 
intravenously injected into each mouse. HCV titer reached approximately 108 copies/mL and 
was stable after 4 weeks of HCV injection and persistently infected for 12 weeks. Here, I used 
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mice after 5 weeks post infection and tested for 2 weeks. The mice were treated for 14 days with 
RO8191 30 mg/kg/day orally or PEG-IFN-α2a 30 µg/kg subcutaneously twice weekly. HCV 
RNA in serum was extracted using the acid guanidinium-phenol-chloroform method. 
Quantification of HCV RNA was performed using real-time RT-PCR based on TaqMan 
chemistry, as described [75]. HCV inoculations, drug administration, blood collection, and 
euthanasia were performed under ether anesthesia. Blood samples were taken from the orbital 
vein and sera were immediately isolated. The protocols for animal experiments were approved 
by the local ethics committee. The animals received humane care according to NIH guidelines. 
Patients gave written informed consent before sampling. 
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Table 1. Culture medium for cell lines. 
Cell Medium Supplement 
HCT116  MaCOY5A L-Glu, 10 % FBS 
Colo201  RPMI 10 % FBS 
WiDr  MEM 
Non essential amino acid (NEAA), 10 % 
FBS 
T47D  RPMI 
HEPES, D-Glu, 0.2 IU/mL bovine insulin, 
10 % FBS 
MDA-MB-231 Leibovitz's L-15 NaHCO3, 10 % FBS 
MDA-MB-435s Leibovitz's L-15 10 mg/ml insulin, 15 % FBS 
KPL4  DMEM (low-Glc) 5 % FBS 
PC3  F-12K 10 % FBS 
DU145 MEM NEAA, Sodium pyruvate (SP), 10 % FBS 
22Rv1 RPMI HEPES, D-Glu, SP, 10 % FBS 
KYSE-150 
49% RPMI, 
49% Ham's F12 
2 % FBS 
Calu-1  MaCOY5A L-Glu, 10 % FBS 
QC56  RPMI 10 % FBS 
A549 F-12K 10 % FBS 
NCl-H460  RPMI 10 % FBS 
Panc-1  DMEM (high-Glc) 10 % FBS 
BxPC3 RPMI HEPES, D-Glu, L-Glu, SP, 10 % FBS 
cFPAC IMDM 10 % FBS 
AsPC1  RPMI 15 % FBS 
Hs766T DMEM (high-Glc) 10 % FBS 
HT1080 MEM NEAA, SP, 10 % FBS 
2fTGH MEM NEAA, SP, 10 % FBS 
U1A MEM NEAA, SP, 10 % FBS 
U5A MEM NEAA, SP, 10 % FBS 
Vero MEM NEAA, SP, 10 % FBS 
MEFs DMEM (high-Glc) 10 % FBS 
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Table 2. Primer sequences and Universal Probe Library for RT-PCR. 
Target UPL Forward Primer Reverse Primer 
HCV IRES 75 CATGGCGTTAGTATGAGTGTCG GGTTCCGCAGACCACTATG 
OAS1 37 GGTGGAGTTCGATGTGCTG AGGTTTATAGCCGCCAGTCA 
MxA 79 TTCAGCACCTGATGGCCTA AAAGGGATGTGGCTGGAGAT 
PKR 62 TTTGGACAAAGCTTCCAACC CGGTATGTATTAAGTTCCTCCATGA 
ADAR 39 CGAGAATCCCAAACAAGGAA CTGGATTCCACAGGGATTGT 
BST2 25 CCACCTGCAACCACACTG CCTGAAGCTTATGGTTTAATGTAGTG 
Viperin 39 TGCTTTTGCTTAAGGAAGCTG TCCCCGGTCTTGAAGAAAT 
ICAM-1 71 CCTTCCTCACCGTGTACTGG AGCGTAGGGTAAGGTTCTTGC 
IRF-1 36 GAGCTGGGCCATTCACAC TTGGCCTTCCACGTCTTG 
STAT1 87 CTGCTCCTTTGGTTGAATCC GCTGAAGTTCGTACCACTGAGA 
SOCS1 87 GCCCCTTCTGTAGGATGGTA CTGCTGTGGAGACTGCATTG 
ISG56 9 AGAACGGCTGCCTAATTTACAG GCTCCAGACTATCCTTGACCTG 
RIG-I 69 TGGACCCTACCTACATCCTGA GGCCCTTGTTGTTTTTCTCA 
MDA5 36 AGGCACCATGGGAAGTGAT ATTTGGTAAGGCCTGAGCTG 
LGP2 71 GCCTTGCAAACAGTACAACCT TCTTCAGCAAGTCCCCAAAC 
IFIT3 80 GCAGAGACACAGAGGGCAGT TGGCATTTCAGCTGTGGA 
USP18 75 TCCCGACGTGGAACTCAG CAGGCACGATGGAATCTCTC 
ISG15 76 GCGAACTCATCTTTGCCAGT AGCATCTTCACCGTCAGGTC 
Herc5 53 TGGATTGCTGATGTGGAGAC CAGGAGATGAAAATATCTCTTGGAT 
IP-10 34 GAAAGCAGTTAGCAAGGAAAGGT GACATATACTCCATGTAGGGAAGTGA 
JAK1 47 GAAAATCCAGTTTGCTTCTTGG CATGGCATTGCAGTCCTCT 
JAK2 50 GGTGAAAGTCCCATATTCTGGT AGGCCACAGAAAACTTGCTC 
Tyk2 1 TGGCTTGCTTGAGTTGACAC ATCCCCAACGGGCTTACT 
IFNAR1 65 ATTTACACCATTTCGCAAAGC CACTATTGCCTTATCTTCAGCTTCT 
IFNAR2 22 GCCTCCCCAAAGTCTTGAA CCCACACTTTCTTCTTTCTGTTG 
IRF9 77 AGCCTGGACAGCAACTCAG AACTGCCCACTCTCCACTTG 
STAT2 21 CATACTAGGGACGGGAAGTCG ATTCTGCAGCATTTCCCACT 
murine Oas1b 1 CCTGGTCACGCACTGGTA CCCATACTCCCAGGCATAGA 
murine Pkr 1 CAGAGCCTGCACCTGAAGTA GCCATTTTTCCTCCCAGTG 
murine Mx1 53 TTCAAGGATCACTCATACTTCAGC GGGAGGTGAGCTCCTCAGT 
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murine Cxcl10 3 GCTGCCGTCATTTTCTGC TCTCACTGGCCCGTCATC 
murine Ifit3 3 TGAACTGCTCAGCCCACA TCCCGGTTGACCTCACTC 
murine Isg15 71 AGTCGACCCAGTCTCTGACTCT CCCCAGCATCTTCACCTTTA 
murine Mda5 82 CTATTAACCGTGTTCAAAACATGAA CACCTGCAATTCCAAAATCTTA 
murine Rig-i 73 GAAGATTCTGGACCCCACCTA TGAATGTACTGCACCTCCTCA 
murine Socs1 20 GTGGTTGTGGAGGGTGAGAT CCTGAGAGGTGGGATGAGG 
murine Stat1 80 GCAGCACAACATACGGAAAA TCTGTACGGGATCTTCTTGGA 
murine Usp18 13 GCTTGACTCCGTGCTTGAG CGGGAGTCCACAACTTCACT 
murine Tnf 49 TCTTCTCATTCCTGCTTGTGG GGTCTGGGCCATAGAACTGA 
murine Il6 6 GCTACCAAACTGGATATAATCAGGA CCAGGTAGCTATGGTACTCCAGAA 
murine Il10 41 CAGAGCCACATGCTCCTAGA GTCCAGCTGGTCCTTTGTTT 
murine Il12a 49 CCATCAGCAGATCATTCTAGACAA CGCCATTATGATTCAGAGACTG 
murine Il12b 27 GATTCAGACTCCAGGGGACA TGGTTAGCTTCTGAGGACACATC 
murine Ccl2 62 CATCCACGTGTTGGCTCA GATCATCTTGCTGGTGAATGAGT 
murine Ccl3 40 TGCCCTTGCTGTTCTTCTCT GTGGAATCTTCCGGCTGTAG 
murine Ccl4 1 GCCCTCTCTCTCCTCTTGCT GAGGGTCAGAGCCCATTG 
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Table 3. siRNA sequences. 
siRNA Dharmacon ID Sequence 
STAT1-1 J-003543-07 5' - CUACGAACAUGACCCUAUC - 3'  
STAT1-2 J-003543-09 5' - AGAAAGAGCUUGACAGUAA - 3'  
STAT2-1 J-012064-06 5' - GGACUGAGGAUCCAUUAUU - 3'  
STAT2-2 J-012064-08 5' - GAUUUGCCCUGUGAUCUGA - 3'  
IRF9-1 J-020858-07 5' - CCACCGAAGUUCCAGGUAA - 3'  
IRF9-2 J-020858-08 5' - GCGUGGAGCUCUUCAGAAC - 3'  
JAK1-1 J-003145-09 5' - CCACAUAGCUGAUCUGAAA - 3'  
JAK1-2 J-003145-12 5' - CGGAUGAGGUUCUAUUUCA - 3'  
JAK2-1 J-003146-12 5' - UUACAGAGGCCUACUCAUA - 3'  
JAK2-2 J-003146-13 5' - AAUCAAACCUUCUAGUCUU - 3'  
Tyk2-1 J-003182-09 5' - GCACAAGGACCAACGUGUA - 3'  
Tyk2-2 J-003182-10 5' - CAAUCUUGCUGACGUCUUG - 3'  
IFNAR1-1 J-020209-05 5' - GCGAAAGUCUUCUUGAGAU - 3'  
IFNAR1-2 J-020209-06 5' - UGAAACCACUGACUGUAUA - 3'  
IFNAR2-1 J-015411-06 5' - GAGUAAACCAGAAGAUUUG - 3'  
IFNAR2-2 J-015411-07 5' - CACCAGAGUUUGAGAUUGU - 3'  
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1-4. Results 
Identification of antiviral small-molecule IFN agonists by high-throughput chemical 
library screening  
HCV replicon cells, which were established ten years ago [45] using a cell line that 
expresses the HCV genotype 1b subgenomic replicon [66], possess a luciferase gene as a 
reporter optimized for use in a robust HTS system. The HTS system provides in-depth analysis 
of primary screening results, including detailed information regarding potency, efficacy and 
structure-activity relationships. IFNs show strong inhibition using this system and have been 
used as a positive control in the assay. Many compounds, including HCV protease inhibitors 
and HCV polymerase nucleoside/non-nucleoside analogs, have been assessed and are being 
developed for clinical testing. Analysis of data from the combination of target/counterscreen 
HTS, data from other assays measuring cellular toxicity, in vitro sphingolipid biosynthesis and 
HCV enzymatic activity (including protease and polymerase) allowed me to select compounds 
with potentially novel modes of action from the primary screen.  
A secondary IFN signal assay, using a luciferase reporter gene which was located 
downstream of the ISRE, eliminated assay-related false-positive compounds. Of the remaining 
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anti-HCV replicon compounds, one of the most active was an imidazonaphthyridine with the 
structural formula 8-(1, 3, 4-oxadiazol-2-yl)-2, 4-bis [1, 2-a] [1, 8] (trifluoromethyl) imidazo 
naphthyridine (RO4948191, hereinafter RO8191) (Fig. 1a). This compound strongly suppressed 
HCV replicon activity at 72 h in a dose-dependent manner (Fig. 1b, left graph) without inducing 
host cell toxicity, as measured by the WST-8 (Fig. 1b, right graph) and CellTiter-Glo assays 
(data not shown). The IC50 (50% inhibitory concentration) of the compound in an anti-HCV 
replicon assay was 200 nM. The compound suppressed viral replication within 24 h and showed 
even more effective inhibition, without cytotoxicity, after 7 days (Fig. 1c). In addition, the HCV 
RNA replicon levels significantly decreased after incubation with the compound for 72 h, as 
determined by real-time RT-PCR analysis (Fig. 2a). Immunostaining showed that levels of the 
proteins HCV NS3 and NS4A, which are localized mainly in the perinuclear region of the 
replicon cells, were also reduced after RO8191 treatment for 24 h (Fig. 2b). This treatment also 
resulted in the disappearance of viral proteins such as NS3, NS4A/B, and NS5A/B, as shown by 
western blot analysis (Fig. 2c). The luciferase activity of HCV subgenomic genotype 2 replicon 
cells (JFH1, data not shown) and, surprisingly, the HCV viral titer of JFH1 [82] in a Huh-7/K4 
cell line were also reduced by RO8191 treatment (Fig. 2d). 
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Figure 1. Identification of a small molecule that inhibits HCV replication.  
(a) The chemical structure of RO8191. (b) After treatment with various concentrations of 
RO8191 or 100 IU/mL IFN-α for 72 h, HCV replication levels were examined using a luciferase 
assay (left graph), and cell viabilities were determined using a WST-8 assay (right graph). The 
mean values and their SDs were recorded for treated cells as a percentage of the values for 
untreated cells, and the values represent the means of 3 independent experiments. (c) After 
treatment with various concentrations of RO8191 for 24 h (left graph) or 7 d (right graph), the 
replication levels of HCV RNA (genotype 1b) were analyzed using a luciferase assay, and cell 
viability was determined using a WST-8 assay. The data are mean values, and the bars indicate 
the standard deviations based on triplicated results. 
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Figure 2. RO8191 inhibits HCV replication.  
(a) Total RNA was extracted from HCV replicon cells cultured with the indicated concentration 
of RO8191 or 100 IU/mL IFN-α for 72 h; HCV RNA levels were analyzed using real-time 
RT-PCR. The mean values and their SDs were recorded for treated cells relative to the mRNA 
levels of β-actin, and are shown as a percentage of untreated cells. The values represent the 
means of 3 independent experiments. (b) HCV replicon cells were treated with control medium 
(left panels) or 10 µM RO8191 (right panels) for 24 h and immunostained with Hoechst 33452 
(blue), anti-NS3 antibody (green), and anti-NS4A antibody (red). The results were then merged 
(yellow). (c) HCV replicon cells were treated with the indicated concentrations of RO8191 or 
100 IU/mL IFN-α for 72 h. Whole cell lysates were immunoblotted with antibodies specific to 
the indicated HCV NS proteins. (d) After infection with the HCV JFH1 strain, Huh-7/K4 cells 
were treated with the indicated concentrations of RO8191 for 72 h. Total RNA was extracted, 
and the HCV RNA levels were analyzed using quantitative real-time RT-PCR. 
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RO8191 induces IFN signals, ISGs expression and JAK/STAT phosphorylation 
To clarify whether RO8191 shows inhibitory activity against another RNA virus, I tested 
its action in EMCV-infected A549 cells. RO8191 showed a cell-protective activity against 
EMCV infection similar to that of IFN-α (Fig. 3). Because IFN-α is the most common host cell 
factor to exert its antiviral activity against HCV [9, 33] by inducing ISG expression [71, 72], I 
compared the gene expression profiles of IFN-α and RO8191 by conducting a global-scale 
DNA microarray analysis to identify genes, especially ISGs [11], that were regulated by 
RO8191. As expected, RO8191 increased the expression of some ISGs (Fig. 4a). The 
microarray analysis also showed that RO8191 induced the expression of IP-10 (CXCL10), 
known as an ISG; though in HCV replicon cells, RO8191 did not induce the genes encoding 
inflammatory cytokines and chemokines (Fig. 4b). And, a reporter gene assay was performed 
using an NF-κB reporter gene. I transiently transfected the reporter gene to HCV-naïve HuH-7 
cells, and then treated them with RO8191 or TNF-α. In Huh-7 cells, NF-κB reporter gene was 
activated by TNF-α treatment, but not by RO8191 (Fig. 4c). These results suggest that RO8191 
induce the IFN-like gene expression specifically. 
Real-time RT-PCR analysis also revealed that RO8191 induced many ISGs similar to those 
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expressed in IFN-α-treated cells (Fig. 5a), suggesting that the antiviral mechanism of RO8191 
depends on ISG expression. In addition to HCV replicon cells, I tested the compound in several 
cancer cell lines and normal human primary hepatocytes (Hc cells). Real-time RT-PCR analysis 
showed that RO8191 induced ISG expression in cultured cell lines and human primary 
hepatocytes (Table 4 and Fig. 5b). These results suggest that RO8191 induces an IFN signal, 
and that the application in clinical of RO8191 is not limited to suppressing HCV infection.  
As mentioned earlier, type I IFNs phosphorylate JAK kinases and STAT proteins by 
inducing a heterodimerization of both IFNAR1 and IFNAR2, and the complexes thus formed 
transduce signals from IFN. Since RO8191 induces ISGs in a similar profile to IFN-α, I 
examined the phosphorylation of IFN signaling molecules. Immunoblotting analyses were 
performed to detect phosphorylated tyrosine (Tyr) and serine (Ser) residues of the STATs and 
JAK kinases using cells that were treated with 50~5000 times the HCV replicon IC50s of 
RO8191, IFN-α, IFN-β, and IFN-γ (type II IFN). The degree to which both RO8191 and IFN-β 
phosphorylated STAT1, STAT5, and STAT6 was similar, as shown in Fig. 6, and the 
phosphorylation level of STAT2 by RO8191 was quite similar to that of IFN-α. Interestingly, 
STAT3 and JAK1 were more strongly phosphorylated by RO8191 than by IFN-α, -β, or -γ. On 
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the other hand, Tyk2 was phosphorylated by type I IFNs, but not by IFN-γ or RO8191, 
indicating that Tyk2 is dispensable for RO8191 activity (Fig. 6). Taken together, the 
phosphorylation profile of STAT proteins by RO8191 is generally similar to that of type I IFNs, 
and the phosphorylation profiles of STAT1–3, 5, 6, and JAK1 in HCV replicon cells treated 
with RO8191 or type I IFNs suggest a common mechanism that differs from the mechanism in 
cells treated with type II IFN. 
Imiquimod, an IFN inducer and a TLR 7 agonist [24], and other small-molecule ligands 
recognized by TLRs and RIG-I–like receptors are known to induce ISG expression by inducing 
IFN [31]. The chemical structure of RO8191 is similar to imiquimod so I examined whether 
RO8191 has an activity like imiquimod. However, imiquimod did not affect HCV replicon cells 
(Fig. 7a), nor stimulate STAT1 phosphorylation, whereas RO8191 caused prolonged STAT1 
activation (for up to 8 h post-treatment; Fig. 7b). RO8191 is actually a small-molecule and I 
could not exclude the possibility that the antiviral activity might be induced through TLRs. To 
confirm that, I tested ISG induction using Tlr3, 4, 7 and 9 KO MEF [23, 24, 27, 84]. I treated 
the MEFs with RO8191 or murine IFN-αA for 8 h and both induced Oas1b mRNA in wild type 
and Tlr-KO MEFs (Fig. 7c), demonstrating that RO8191 induces ISG expressions 
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independently of TLRs. To exclude the possibility that RO8191 acts by inducing type I IFN, I 
examined its effects in Vero cells that lack the IFN gene locus [12, 51]. Whereas imiquimod did 
not show IFN-like effects in Vero cells, RO8191 and IFN-α induced the ISRE activation (Fig. 
7d), indicating that RO8191 can act without inducing IFN and is quite distinct from imiquimod. 
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Table 4. RO8191 induces OAS1 expression in various cell lines. 
Cancer Cell line Fold change ± SD 
Colon 
HCT116  2333.3  ± 129.2  
Colo201  60.1  ± 6.6  
WiDr  32.2  ± 3.2  
Breast 
T47D  660.2  ± 12.2  
MDA-MB-231  638.3  ± 33.5  
MDA-MB-435s  34.2  ± 0.6  
KPL4  26.9  ± 4.0  
Prostate 
PC3  325.3  ± 34.5  
DU145 82.1  ± 1.2  
22Rv1 11.9  ± 1.2  
Gastric KYSE-150 140.1  ± 11.8  
Lung 
Calu-1  43.2  ± 1.7  
QC56  20.8  ± 2.5  
A549 9.3  ± 1.2  
NCl-H460  3.8  ± 0.2  
Pancreas 
Panc-1  40.3  ± 7.3  
BxPC3 35.2  ± 1.3  
cFPAC 19.9  ± 2.0  
AsPC1  12.1  ± 4.3  
Hs766T 3.6  ± 0.6  
Connective tissue HT1080 36.2  ± 5.4  
Derived from HT1080 2fTGH 21.5 ± 1.2 
 
RO8191 induces OAS1 expression in various cell lines. Total RNA was extracted from various 
cell lines cultured in the presence of 50 mM RO8191 for 8 h, and OAS1 mRNA levels were 
then measured using real-time RT-PCR. The mean fold change induction and SD of treated 
cells compared to untreated cells is based on triplicate determination. 
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Figure 3. Anti-EMCV effect by RO8191.  
The cytopathic effect of EMCV infection was inhibited by the indicated concentrations of 
RO8191 or IFN-α. Viable cells were stained with crystal violet. The data shown are the mean 
values and SDs based on experiments performed in quadruplicate.  
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Figure 4. RO8191 induces IFN-like signals.  
(a) The fold change in RO8191-treated or IFN-α-treated HCV replicon cells is plotted in 
comparison to untreated cells. All 54,675 probes (black circles) and 318 ISG probes (red 
circles) are shown. The red lines to the left and below the center black line indicate 0.5-fold 
change, and red lines to the right and above the black line indicate 2.0-fold change. (b) Gene 
expression levels of cytokines and chemokines at indicated time points in the RO8191-treated 
HCV replicon cells by DNA microarray analysis. (c) NF-κB reporter gene was transiently 
transfected into the Huh-7 cells, and at 48 h after transfection, the cells were treated with 0.3 
ng/mL TNF-α or 50 µM RO8191 and a further 4, 8 or 24 h later, the luciferase activity was 
measured. The values indicate the mean of fold change.   
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Figure 5. RO8191 induces ISGs expression.  
(a) ISG expression levels were measured using real-time RT-PCR. Total RNA was extracted 
from HCV replicon cells cultured in the presence of 50 µM RO8191 or 100 IU/mL IFN-α for 2 
or 8 h and known ISGs were analyzed. Asterisk indicates 2-h treatment with agents. The values 
shown are the mean fold change induction compared to the mRNA level of human β-actin and 
the fold change induction compared to untreated cells. (b) ISG expression levels were measured 
using real-time RT-PCR. The values are listed relative to the mRNA level of human b-actin and 
represent the mean fold change induction compared to untreated cells. Total RNA was extracted 
from Hc cells treated with the indicated concentrations of RO8191 or 100 IU/mL IFN-α for 8 h, 
and the mRNA levels of OAS1, MxA, and PKR (means and SDs) were measured using 
real-time RT-PCR. 
  
  
a 
Fold change by RO8191 (50 µM) 
Fo
ld
 c
ha
ng
e 
by
 IF
N
α
 (1
00
 IU
/m
L)
 



-I


"



 !

-1
-1*







!
-10



	

	
		
			
				
					
 	 		 			 				 					
OAS1 mRNA 
0 
2 
4 
6 
8 
10 
12 
Fo
ld
 c
ha
ng
e 
of
 c
on
tro
l 
MxA mRNA 
0 
500 
1000 
1500 
2000 
2500 
Fo
ld
 c
ha
ng
e 
of
 c
on
tro
l 
0.5 5 50 IFN-α
RO8191 (µM) 
PKR mRNA 
0 
1 
2 
3 
4 
5 
6 
Fo
ld
 c
ha
ng
e 
of
 c
on
tro
l 
0.5 5 50 IFN-α
RO8191 (µM) 
0.5 5 50 IFN-α
RO8191 (µM) 
b
 41 
 
 
 
Figure 6. RO8191 activates JAK/STAT pathway. 
HCV replicon cells were treated with various concentrations of the indicated agents for 15 min. 
Total lysates were immunoblotted with antibodies to STATs or JAK kinases. The HCV replicon 
IC50 of IFN-α was 0.4 IU/mL, that of IFN-β was 3 IU/mL, and that of IFN-γ was 0.3 ng/mL. 
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Figure 7. TLR signals cannot induce RO8191-like activity.  
(a) After treatment with various concentrations of imiquimod for 72 h, the replication levels of 
the HCV replicon were analyzed using a luciferase assay, and cell viabilities were determined 
using a WST-8 assay. (b) Western blot analyses of the phosphorylated and total protein levels of 
STAT1 in HCV replicon cells cultured in a medium containing 10 µM RO8191 or 10 µM 
imiquimod at 0.5, 1, 2, 4 and 8 h. (c) Total RNA was extracted from TLR KO MEFs cultured in 
the presence of 50 µM RO8191 or 1,000 IU/mL murine IFN-αA for 8 h, and the Oas1b mRNA 
level was analyzed using real-time RT-PCR. The data shown are the mean fold change 
induction compared to untreated cells, and the bars indicate the standard deviations based on 
triplicated results. (d) ISRE reporter gene activation by RO8191, imiquimod or IFN-α treatment. 
ISRE reporter gene was transiently transfected into Vero cells, and 48 h later the cells were 
treated with RO8191, imiquimod or IFN-α with or without a JAK inhibitor I. After an additional 
8 h, luciferase activity was measured. 
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RO8191 exerts antiviral activity dependent on IFNAR2/JAK1, but is independent of 
IFNAR1/Tyk2 
IFNs require IFN receptor subunits for their activity, and I hypothesized that RO8191 uses 
the IFN receptor to exert anti-HCV activity. To determine the contributions of IFNAR1 and 
IFNAR2 toward the anti-HCV replicon activity of RO8191, I suppressed the expression of these 
receptors using specific siRNA and treated the cells with RO8191 or IFN-α. The knockdown 
efficiency was determined using RT-PCR in the HCV replicon cells transfected with each 
siRNA, as shown in Fig. 8. As expected, a knockdown of each receptor subunit decreased the 
antiviral activity of IFN-α (Fig. 9). IFNAR2 knockdown attenuated the antiviral activity of 
RO8191 (Fig. 9c and d) but, interestingly, IFNAR1 knockdown did not change the antiviral 
activity (Fig. 9a and b), suggesting that RO8191 acts independent of IFNAR1. To address 
whether IFN-α receptor contributes to RO8191 signaling, I evaluated RO8191 using Ifnar1-KO 
MEF cells [4]. I treated Ifnar1-KO MEFs with 50 µM RO8191 or 1,000 IU/mL of murine 
IFN-αA for 8 h and analyzed the expression of murine Oas1b mRNA using real-time RT-PCR. 
Murine IFN induced murine Oas1b mRNA only in wild type MEFs, not in Ifnar1-KO MEFs, 
although RO8191 induced Oas1b in both wild type and Ifnar1-KO MEFs (Fig. 10). Therefore, 
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RO8191 induces IFN-like activity even in Ifnar1-KO MEFs. 
Since IFNAR2 knockdown reduced RO8191 activity, I focused on and analyzed the 
IFNAR2 function using RO8191. First, U5A cells, which do not respond to IFN-α because of 
the lack of IFNAR2 expression [46], were treated with RO8191. Although RO8191 and IFN-α 
did not induce OAS1 expression in the U5A cells, IFNAR2-overexpressing U5A cells were able 
to successfully respond to both RO8191 and IFN-α (Fig. 11a and b). RO8191 also induced the 
OAS1 gene expression in HT1080 and 2fTGH cells, the parental cell lines of U5A cells (Table 
4, lowest and second lowest rows). Second, to elucidate whether RO8191 directly interacts with 
IFNAR2, I obtained a recombinant IFNAR2 ECD protein (N-terminal half of the protein, amino 
acids from Ile27- Lys243). The protein was subjected to SPR spectroscopy using a Biacore 
system to directly evaluate the binding activity of the recombinant protein with its possible 
ligands, RO8191 and IFN-α. The IFNAR2 ECD protein was fixed on the surface of the CM7 
sensor chip by amine coupling, and PEG-IFN-α2a and RO8191 were injected as analytes. I 
comparatively analyzed 0.31 and 0.63 µM of RO8191, and both concentrations showed similar 
binding affinities of 480.5 and 484.5 nM, respectively (Fig. 11c), whereas a chemically 
derivatized compound of RO8191 that cannot inhibit HCV replication did not bind to IFNAR2 
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ECD (data not shown). The SPR results were consistent with 1:1 binding and showed an 
interaction between RO8191 and the IFNAR2 ECD protein in a dose-dependent manner, 
indicating that the compound and IFNAR2 may directly interact on the cell surface. In addition 
to the anti-replicon activity, the phosphorylation of STAT1 by RO8191 was also repressed by 
IFNAR2 knockdown (Fig. 12a), but the knockdown of IFNAR1 did not inhibit the STAT1 
phosphorylation (Fig. 12b), indicating that RO8191 requires IFNAR2 but not IFNAR1 to 
achieve activity. Similarly, the knockdown of JAK1 attenuated the activity of RO8191 and 
IFN-α (Fig. 13a and b), while, in contrast, Tyk2 and JAK2 were not required for RO8191 
activity (Figs. 13c, d and 14). The phosphorylation of STAT1 by RO8191 was also inhibited by 
a knockdown of JAK1 (Fig. 15a), but not by a knockdown of Tyk2 (Fig. 15b), indicating JAK1 
essentiality for the antiviral activity of RO8191. To confirm Tyk2-independency, I used U1A 
(Tyk2-deficient) cells and the parental cell, 2fTGH [81], and treated them with 50 µM RO8191 
or 100 IU/mL IFN-α for 8 h to analyze the expression of OAS1. As expected from previous 
reports [43], IFN-α induced the OAS1 expression only in 2fTGH cells but not in U1A cells; 
however, RO8191 induced the expression in both 2fTGH and U1A cells significantly (Fig. 16). 
Thus, RO8191 activates ISGs in a JAK1-dependent and Tyk2-independent manner; on the other 
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hand, IFN-α depends on both factors. Next, I conducted a knockdown of the transcription 
factors related to type I IFNs activity, STAT1, STAT2 and IRF-9, to clarify whether RO8191 
required these factors for antiviral activity. As expected, STAT1-siRNAs partially blocked 
IFN-γ activity (Fig. 17), which is mediated by STAT1 homodimers [69]. STAT1 was 
significantly phosphorylated by both RO8191 and IFN-α (Fig. 6); however, the STAT1 
knockdown affected neither RO8191 nor IFN-α activity (Fig. 17). I also analyzed the impact of 
STAT1 knockdown on OAS1 induction by RO8191, and found OAS1 induction by RO8191 
was inhibited (Fig. 18). STAT2 and IRF9 knockdown attenuated the inhibitory activity of both 
RO8191 and IFN-α (Figs. 19 and 20). In summary, RO8191 only binds to IFNAR2 and 
activates JAK1, STATs, and IRF9, thereby exhibits type I IFN-like activity (Fig. 21). 
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Figure 8. Knockdown efficacy in the HCV replicon cells. 
HCV replicon cells transfected with the indicated siRNAs (10 nM). Forty-eight hours after 
transfection, total RNA was extracted, and the mRNA levels were analyzed using real-time 
RT-PCR analysis. The data shown are mean values and SDs relative to the mRNA level of 
human b-actin in non-transfected cells. 
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Figure 9. IFNAR2 siRNA inhibits the antiviral activity of RO8191.  
(a, c) The anti-HCV replicon activity of RO8191 was attenuated by knockdown of IFNAR2 (c), 
but not IFNAR1 (a). Inhibition of HCV replicon replication by each agent is shown (the mean 
and SD from 3 experiments). The HCV replicon cells were transfected with 50 nM of the 
indicated siRNAs (blue, red, and yellow bars). Forty-eight hours after transfection, the HCV 
replicon cells were treated with 1.5 µM RO8191 or 3 IU/mL IFN-α for 24 h. Twenty-four hours 
after treatment with each agent, the replication levels of HCV RNA were analyzed using a 
luciferase assay. (b, d) Serial dilution includes the data shown in Fig. 9a and c (50 nM siRNA). 
The inhibition of HCV replicon replication by each agent is shown (the mean and SD from 3 
experiments). The HCV replicon cells were transfected with various concentrations of the 
indicated siRNAs (blue, red, and yellow bars). Twenty-four hours after treatment with each 
agent, the replication levels of HCV RNA were analyzed using a luciferase assay. Forty-eight 
hours after transfection, the HCV replicon cells were treated with 1.5 µM RO8191 (left graphs) 
or 3 IU/mL IFN-α (right graphs) for 24 h. The data were statistically analyzed using Student’s 
t-test. 
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Figure 10. RO8191 induces IFN-like activity in Ifnar1-KO MEFs. 
Total RNA was extracted from Ifnar1 KO MEFs cultured in the presence of 50 µM RO8191 or 
1,000 IU/mL murine IFN-αA for 8 h, and the Oas1b mRNA level was analyzed using real-time 
RT-PCR. The data shown are the mean fold change induction compared to untreated cells, and 
the bars indicate the standard deviations based on triplicated results. 
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Figure 11. RO8191 requires and binds IFNAR2.  
(a, b) U5A cells that lack IFNAR2 were transfected with either an empty vector or a vector 
expressing the IFNAR2 gene. (a) Forty-eight hours after transfection, the cells were treated with 
50 µM RO8191 (red bars) or 100 IU/mL IFN-α (yellow bars). After an additional 8 h of 
incubation, total RNA was extracted from the U5A cells, and the OAS1 mRNA level was 
measured using real-time RT-PCR. The values shown are relative to the mRNA level of human 
β-actin. (b) Forty-eight hours after transfection, the cells were lysed, and the whole cell lysates 
were immunoblotted with the indicated antibodies. (c) Real-time kinetic SPR analysis of the 
binding of RO8191 to the IFNAR2 ECD (red and blue lines). The results are consistent with 1:1 
binding. PEG-IFN-α2a was also injected as a positive interacting control for IFNAR2 (black 
line, KD: 30 nM). The data were statistically analyzed using Student’s t-test. 
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Figure 12. The phosphorylation of STAT1 was attenuated by a knockdown of IFNAR2 (b) 
but not IFNAR1 (a).  
The HCV replicon cells were transfected with the indicated siRNAs (10 nM). Forty-eight hours 
after transfection, the cells were treated for 15 min with 10 µM RO8191 or 200 IU/mL IFN-α. 
The total lysates were subjected to western blot analysis to analyze the phosphorylated and total 
protein levels of STAT1.  
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Figure 13. JAK1 siRNA inhibits the antiviral activity of RO8191.  
(a, c) The inhibition of HCV replicon replications by each agent is shown (mean and SD). The 
HCV replicon cells were transfected with 50 nM of the indicated siRNAs (blue, red, and yellow 
bars). (a, b) The anti-HCV replicon activity of RO8191 was reduced by knockdown of JAK1 (a) 
but not Tyk2 (b). Forty-eight hours after transfection, the HCV replicon cells were treated with 
1.5 µM RO8191 or 3 IU/mL IFN-α. Twenty-four hours after treatment with each agent, the 
replication levels of HCV RNA were analyzed using a luciferase assay. Serial dilution includes 
the data shown in Fig. 13a and c (50 nM siRNA). The HCV replicon cells were transfected with 
various concentrations of the indicated siRNAs (blue, red, and yellow bars). Forty-eight hours 
after transfection, the HCV replicon cells were treated with 1.5 µM RO8191 (left graphs), 3 
IU/mL IFN-α (right graphs). Twenty-four hours after treatment with each agent, the replication 
levels of HCV RNA were analyzed using a luciferase assay. The data were statistically analyzed 
using Student’s t-test, and differences were considered significant at p values < 0.05. 
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Figure 14. RO8191 induces IFN-like activity in JAK2 siRNA transfected cells. 
The anti-HCV replicon activity of RO8191 was not reduced by a knockdown of JAK2. The 
inhibition of HCV replicon replications by each agent is shown (means and SDs). The HCV 
replicon cells were transfected with various concentrations of the JAK2 siRNAs (blue, red, and 
yellow bars). Forty-eight hours after transfection, the HCV replicon cells were treated with 1.5 
µM RO8191 (upper graph) or 50 ng/mL IFN-γ (lower graph). Twenty-four hours after treatment 
with each agent, the replication levels of HCV RNA were analyzed using a luciferase assay.  
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Figure 15. The phosphorylation of STAT1 was attenuated by knockdown of JAK1 (a) but 
not Tyk2 (b).  
The HCV replicon cells were transfected with the indicated siRNAs (10 nM). Forty-eight hours 
after transfection, the cells were treated for 15 min with 10 µM RO8191 or 200 IU/mL IFN-α. 
Total lysates were subjected to western blot analysis in order to analyze the phosphorylated and 
total protein levels of STAT1. 
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Figure 16. RO8191 induces IFN-like activity in Tyk2-deficient cells. 
Total RNA was extracted from 2fTGH and U1A cells cultured in the presence of 50 µM 
RO8191 or 100 IU/mL IFN-α for 8 h, and the OAS1 mRNA level was analyzed using real-time 
RT-PCR. The data shown are the mean fold change induction compared to untreated cells, and 
the bars indicate the standard deviations based on triplicated results. 
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Figure 17. RO8191 activity in STAT1 siRNA transfected cells. 
The inhibition of HCV replicon replications by each agent is shown (mean and SD). The HCV 
replicon cells were transfected with 50 nM of the STAT1 siRNAs (blue, red, and yellow bars). 
(a) Forty-eight hours after transfection, the HCV replicon cells were treated with 1.5 µM 
RO8191, 3 IU/mL IFN-α, or 50 ng/mL IFN-γ. Twenty-four hours after treatment, the replication 
levels of HCV RNA were analyzed using a luciferase assay. (b) Serial dilution includes the data 
shown in Fig. 17a (50 nM siRNA). The HCV replicon cells were transfected with various 
concentrations of the indicated siRNAs (blue, red, and yellow bars). Forty-eight hours after 
transfection, the HCV replicon cells were treated with 1.5 µM RO8191 (top graph), 3 IU/mL 
IFN-α (middle graph) or 50 ng/mL IFN-γ (bottom graph). Twenty-four hours after treatment, 
the replication levels of HCV RNA were analyzed using a luciferase assay. The data were 
statistically analyzed using Student’s t-test, and differences were considered significant at p 
values < 0.05.  
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Figure 18. OAS1 induction by RO8191 in STAT1 siRNA transfected cells. 
Sixty-four hours after indicated 10 nM siRNA transfection, I treated the cells with 10 µM 
RO8191 for 8h. Then, RNA was extracted from the cells and OAS1 expression was determined 
by RT-PCR. The data are mean values, and the bars indicate the standard deviations. 
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Figure 19. RO8191 activity in STAT2 siRNA transfected cells. 
The inhibition of HCV replicon replications by each agent is shown (mean and SD). The HCV 
replicon cells were transfected with 50 nM of the STAT2 siRNAs (blue, red, and yellow bars). 
(a) Forty-eight hours after transfection, the HCV replicon cells were treated with 1.5 µM 
RO8191, 3 IU/mL IFN-α, or 50 ng/mL IFN-γ. Twenty-four hours after treatment, the replication 
levels of HCV RNA were analyzed using a luciferase assay. (b) Serial dilution includes the data 
shown in Fig. 19a (50 nM siRNA). The HCV replicon cells were transfected with various 
concentrations of the indicated siRNAs (blue, red, and yellow bars). Forty-eight hours after 
transfection, the HCV replicon cells were treated with 1.5 µM RO8191 (top graph), 3 IU/mL 
IFN-α (middle graph) or 50 ng/mL IFN-γ (bottom graph). Twenty-four hours after treatment, 
the replication levels of HCV RNA were analyzed using a luciferase assay. The data were 
statistically analyzed using Student’s t-test, and differences were considered significant at p 
values < 0.05.  
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Figure 20. RO8191 activity in IRF-9 siRNA transfected cells. 
The inhibition of HCV replicon replications by each agent is shown (mean and SD). The HCV 
replicon cells were transfected with 50 nM of the IRF-9 siRNAs (blue, red, and yellow bars). (a) 
Forty-eight hours after transfection, the HCV replicon cells were treated with 1.5 µM RO8191, 
3 IU/mL IFN-α, or 50 ng/mL IFN-γ. Twenty-four hours after treatment, the replication levels of 
HCV RNA were analyzed using a luciferase assay. (b) Serial dilution includes the data shown in 
Fig. 19a (50 nM siRNA). The HCV replicon cells were transfected with various concentrations 
of the indicated siRNAs (blue, red, and yellow bars). Forty-eight hours after transfection, the 
HCV replicon cells were treated with 1.5 µM RO8191 (top graph), 3 IU/mL IFN-α (middle 
graph) or 50 ng/mL IFN-γ (bottom graph). Twenty-four hours after treatment, the replication 
levels of HCV RNA were analyzed using a luciferase assay. The data were statistically analyzed 
using Student’s t-test, and differences were considered significant at p values < 0.05. 
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Figure 21. A model showing the pathways of RO8191 and IFN-α. 
RO8191 binds to IFNAR2 and activates JAK1, STATs, and IRF9, thereby exhibiting type I 
IFN-like activity.   
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RO8191, an IFNAR2 agonist, stimulates IFN signals in mice 
To evaluate whether RO8191 could be a clinical lead for drug development, I studied the 
effects of RO8191 on IFN signaling in mice. The compound or vehicle was orally administered 
to mice and, 24 h after treatment, the liver was removed and examined. The antiviral genes 
Oas1b, Mx1, and Pkr were significantly induced in the livers of mice treated with RO8191 
(Table 5). As expected, gene homologs that were induced in the livers of HCV patients treated 
with PEG-IFN-α2b [67] were also induced in mouse liver (Ifit3, Isg15, Mda5, Rig-I, Socs1 and 
Stat1; Table 5). In addition, genes that had previously been reported to be induced by IFN-β in 
mouse liver [14] were also induced in the livers of RO8191-treated mice (Cxcl10, Ifit3, Isg15, 
Socs1 and Usp18; Table 5). I also measured inflammatory cytokine and chemokine expressions, 
and RO8191 did not significantly induce the expression of these genes (Table 6). To evaluate 
anti-HCV activity of RO8191 in vivo, RO8191 was orally administered to HCV-infected 
humanized liver mice [49]. The results of this humanized liver mice study showed that RO8191 
reduced HCV titer in vivo (Fig. 22). These data show that RO8191 stimulates IFN signaling and 
is an orally available agent in mice. 
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Table 5. ISG expression in the livers of RO8191 treated mice. 
Gene Entrez ID Fold change ± SD p-value 
murine Oas1 NM_001083925 3.0  ± 0.72  0.003  
murine Mx1 NM_010846 2.1  ± 0.15  0.0003  
murine Pkr NM_011163 1.4  ± 0.21  0.009  
murine Cxcl10 NM_021274 1.7  ± 0.63  0.097  
murine Ifit3 NM_010501 2.5  ± 0.48  0.001  
murine Isg15 NM_015783 2.3  ± 0.41  0.002  
murine Mda5 NM_027835 1.6  ± 0.22  0.003  
murine Rig-i NM_172689 2.1  ± 0.16  0.00003  
murine Socs1 NM_009896 2.6  ± 1.04  0.057  
murine Stat1 NM_009283 1.8  ± 0.21  0.001  
murine Usp18 NM_011909 2.6  ± 0.69  0.017  
 
ISG expression levels were measured using real-time RT-PCR. Values are listed relative to the 
mRNA levels of rodent Gapdh and represent the mean fold change induction compared to 
vehicle-administered mice. Twenty-four hours after oral administration of 30 mg/kg RO8191 or 
vehicle (including 10% dimethyl sulfoxide and 10% Cremophor) to mice, total RNA was 
extracted from the mouse livers, and the mRNA levels of murine ISGs were measured using 
real-time RT-PCR. The data shown are the means and SDs of 4 mice per group. The data were 
statistically analyzed using Student’s t-test, and differences were considered significant at p 
values < 0.05. 
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Table 6. Cytokine and chemokine gene expression in the livers of RO8191-treated mice. 
Gene Fold change ± SD  p-value 
Tnf 2.93  ± 2.37  0.20131  
Il6 1.35  ± 1.74  0.81617  
Il10 2.53  ± 0.80  0.07623  
Il12a Undetectable 
 
Il12b 1.07  ± 0.09  0.76622  
Ccl2 2.63  ± 1.70  0.13037  
Ccl3 1.36  ± 0.90  0.58189  
Ccl4 3.08  ± 2.52  0.16316  
 
Gene expressions of cytokines and chemokines were determined by real-time RT-PCR analysis. 
Samples are the same ones that were used for Table 5. Values are listed relative to the mRNA 
levels of rodent Gapdh and represent the mean fold change induction compared to 
vehicle-administered mice. The data shown are the means and SDs of 4 mice per group. The 
data were statistically analyzed using Student’s t-test, and differences were considered 
significant at p values < 0.05. 
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Figure 22. RO8191 reduced HCV titer in vivo. 
The mice were treated for 14 days with RO8191 30 mg/kg/day orally or PEG-IFN-α2a 30 µg/kg 
subcutaneously twice weekly. Time course of serum HCV RNA levels in mice treated with 
RO8191 (red line, n=5), PEG-IFN-α2a (blue line, n=4) or no treatment (green line, n=8) is 
shown. The data are mean values, and the bars indicate the standard deviations. 
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1-5. Discussion  
In this study, I identified a small-molecule IFN receptor agonist, RO8191, by quantitative 
HTS of a chemical library. This compound showed antiviral activity against both HCV and 
EMCV, suggesting a broad spectrum of target viruses. To learn more about the possible 
mechanism of action of IFN signal induction by RO8191, I investigated IFN-induced signaling 
and ISG induction by the small-molecule compound in vitro and in vivo. A comparison of 
microarray expression profiles in HCV replicon cells stimulated by IFN-α or RO8191 indicates 
that the IFN signal was induced not only by IFNs, but also by the small-molecule compound 
(Figs. 4a and 5a). Thus, this compound is an IFN-α-like small molecule, but the mechanism of 
the RO8191 antiviral activity remained unknown. Therefore, I examined the JAK/STAT 
activation pathway, which includes key players in the IFN signaling cascade.  
Like type I IFNs, RO8191 significantly phosphorylates and activates STATs, in particular, 
STAT1 and STAT2 (Fig. 6). Intriguingly, in HCV replicon cells, STAT1 expression 
knockdown did not affect the antiviral activity of RO8191 or IFN-α, although IFN-γ activity 
was inhibited (Fig. 17). These data suggest that, in addition to inducing similar gene expression, 
RO8191 and IFN-α exhibit similar STAT phosphorylation profiles. Although RO8191- and 
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IFN-α-mediated antiviral activity remained constant when STAT1 expression was reduced, this 
could be because IFN-α signaling in HuH-7 cells requires minimal amounts of STAT1 protein 
and STAT1 expression was not reduced below such a critical threshold by siRNA in my system. 
In contrast, the inhibitory activity of RO8191 was attenuated to the same extent as that of IFN-α 
when the expression of other components of ISGF3 (STAT2 and IRF-9) were reduced by 
siRNA (Figs. 19 and 20). Incidentally, STAT1 siRNA did not attenuate RO8191 or IFN activity 
in EMCV-infected A549 cells (Fig. 23), which supports the notion that STAT2 is an essential 
component of type I IFN signaling [42]. Type I IFN stimulates the formation of other 
STAT-containing complexes, including STAT1:STAT1, STAT3:STAT3 and STAT5:STAT5 
homodimers, as well as STAT1:STAT3 and STAT2:STAT6 heterodimers [20, 21, 44]. Like 
IFN, RO8191 induced the phosphorylation of STAT1 and STAT2, which function as a gateway 
to the type I IFN signal cascade, and stimulated the phosphorylation of STAT3, 5 and 6. 
Another possible cause for the fact that STAT1 knockdown did not show any effect on RO8191 
inhibition could be compensation by these IFN signaling-stimulated STAT complexes. This 
finding matches the recent report by Perry et al. on the STAT dependency of IFN activity 
against Dengue virus, that belongs to flavivirus [57]. They showed that STAT2 mediates IFN 
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antiviral signals even in STAT1 KO cells and they discussed the possibility that other STAT 
family proteins would compensate for STAT1 deficiency. In summary, with regards to the 
activation of transcription factors and ISG expression, RO8191 and IFN-α mediate the same 
pathway. 
IFNs activate JAK kinases via IFN receptors to induce STAT phosphorylation. RO8191 
robustly phosphorylated JAK1 (Fig. 6) in comparison with IFN-α or -β and therefore I focused 
on IFNAR2 (a JAK1-binding subunit of the type I IFN receptor). As with IFN-α, the activity of 
RO8191 was inhibited by IFNAR2 knockdown (Fig. 9c). The suggestion that IFNAR2 is an 
essential molecule for RO8191-induced signal transduction is supported by the fact that an 
IFNAR2-deficient cell line, U5A, did not respond to RO8191. Furthermore, after IFNAR2 
expression had been complemented in the U5A cells, ISG induction by both RO8191 and IFN-α 
recovered (Fig. 11a and b). The mechanism was directly explained by SPR spectroscopy, which 
showed an interaction between RO8191 and the IFNAR2 ECD (Fig. 11c). RO8191 strikingly 
phosphorylates the IFNAR2-associated kinase JAK1, when compared to other IFN-treated cell 
lysates (Fig. 6). JAK1 siRNA expression inhibited RO8191 activity (Fig. 13a), indicating that 
JAK1 is also an essential molecule for RO8191 activity. Interestingly, RO8191 activity remains 
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static when IFNAR1 expression is knocked down, unlike IFN-α activity (Fig. 9a). The 
IFNAR1-binding-kinase Tyk2 is not required for RO8191 activity (Fig. 13b) and Tyk2 was not 
phosphorylated (Fig. 6) by RO8191. Also, RO8191 induced its signal even in the Ifnar1 KO 
MEF and the Tyk2-deficient cell line (Figs. 10 and 16). IFN-α induces a signal via 
IFNAR1/Tyk2 and IFNAR2/JAK1, although RO8191 and IFN-α induce common ISGs, 
RO8191 activity was dependent only on IFNAR2/JAK1.  
I therefore propose a novel model of the induction of IFN-like signal transduction by this 
small molecule (Fig. 21). So far, the IFNAR2 homodimer has been suggested to play various 
roles in IFN signal transduction [43, 55, 59], and RO8191 would induce the ISG expression via 
such IFNAR2 homodimer. For type I IFN, both IFNAR1 and IFNAR2 cooperate and induce 
phosphorylation of STATs via JAK1 and Tyk2. Conversely, for RO8191, IFNAR2 alone, as a 
homodimer, activates JAK1 phosphorylation and subsequent STATs activation. Experiments 
using siRNA and deficient cells have also shown that IFNAR1 and Tyk2 were not required to 
induce antiviral activity in the RO8191 compound pathway. These findings suggest a novel 
aspect of the IFN signaling pathway that may contribute to the understanding of other molecular 
signaling in IFN pathways.  
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RO8191 is a small molecule whose oral administration is feasible and effective in a murine 
model (Table 5 and Fig. 22). In the chimeric mice study, the anti-HCV effect of RO8191 and 
PEG-IFN was similar in that they both showed strong activity at day 1 after treatment with 
subsequent weak suppression of HCV replication possibly due to the immunodeficiency of 
chimeric mice. Further development of RO8191 by using rational chemical modifications is 
therefore required to produce more potent molecules for testing as an antiviral molecule which 
will substitute current recombinant IFN. Although RO8191 has the potential to cause IFN-like 
adverse effects, further development of the small-molecule agonist offers the advantages of 
inexpensive production cost, convenient oral administration, dose-control to reduce some 
adverse effects, and potentially increased activity versus current recombinant IFNs. 
Whereas oral NS3 protease inhibitors in monotherapy development yield resistant viruses 
[25, 48], these protease inhibitors show a significantly high rate of SVR when combined with 
PEG-IFN [30, 60] and a NS5B polymerase inhibitor also shows additive efficacy in 
combination with PEG-IFN [34]. In addition to the results of the in vivo study, I found that 
RO8191 induced ISGs at a level similar to IFN-α in human primary hepatocytes (Fig. 5b); I 
therefore expect that RO8191 will show IFN-like activity in clinical use. As an alternative 
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strategy to protease/polymerase inhibitors with PEG-IFN, the combined use of these 
direct-acting antiviral agents with RO8191 in a new oral regimen may help overcome some of 
the delivery problems associated with current IFNs. SVR rates of individuals infected with 
HCV genotype 1 have increased from 5-20% with IFN monotherapy and up to 50% with a 
combination of IFN and RBV. However, the refractory patients in this therapy constitute an 
unmet medical need. Thus, the development of a novel IFN receptor agonist, used alone or in 
combination with direct-acting antiviral drugs, will add a new milestone to the treatment of 
chronic hepatitis C. In addition to HCV infection, type I IFNs have been approved for the 
treatment of multiple clinical conditions, including hairy cell leukemia, malignant melanoma, 
AIDS-related Kaposi’s sarcoma, multiple sclerosis, and chronic hepatitis B [22]. Thus, R08191 
shows strong potential as a lead compound for IFN substitutes. 
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Figure 23. Anti-EMCV activity of RO8191 in STAT siRNA transfected cells.  
I transfected 50 nM STAT1- or STAT2-siRNA to A549 cells, and after 72 h, I infected EMCV 
to the cells and treated them with 1 µM RO8191 or 2 IU/mL IFN-α. After additional 48 h 
incubation, I evaluated the cell viability by staining with crystal violet. 
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Chapter 2 
 
Hepatic IP-10 expression is more strongly associated with 
liver fibrosis than IL28B single nucleotide polymorphisms in 
hepatocellular carcinoma resected patients with chronic hepatitis 
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2-1. Abstract 
SNPs around IL28B and ISG expression are predictors of response to standard therapy 
involving IFN for chronic HCV infection. I analyzed the association between these predictors to 
improve the prediction of the response to IFN therapy after liver resection for HCC. Data were 
collected from 74 patients with HCV-induced HCC. The IL28B genotype and hepatic ISG 
mRNA levels were analyzed to clarify their association, focusing on the progression of liver 
fibrosis. Fifty patients were identified as having major alleles (rs8099917 TT) and the remaining 
24 patients had minor alleles (rs8099917 TG or GG). Hepatic ISG15 expression was lower in 
the IL28B major group than that in the IL28B minor group (p < 0.005). IP-10 expression was 
similar between the IL28B major and minor groups (p = 0.44). IP-10 expression was elevated 
with advancing stages of liver fibrosis in HCV-infected patients (p = 0.005). In patients with 
mild or no fibrosis, the IL28B major group had lower IP-10 expression than the IL28B minor 
group (p = 0.02). However, in patients with advanced fibrosis, IP-10 expression was not 
different between the IL28B major and minor groups (p = 0.66). Hepatic ISG15 expression is 
associated with IL28B polymorphisms, while IP-10 is strongly affected by liver fibrosis. 
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2-2. Introduction 
HCV infection affects 170 million people worldwide, and most acute HCV infections 
become chronic, with some progression to liver cirrhosis or HCC. Current standard therapy 
against chronic HCV infection includes PEG-IFN-α and RBV [19], which achieve a sustained 
SVR in only 50% of patients chronically infected with the HCV genotype 1 [17, 50, 85]. 
HCV infection induces IFN production via innate immune cascades [47, 65]. IFN consists 
of type I (IFN-α, β, and others), II (only IFN-γ), and III (IFN-λs; interleukin, or IL28A/B and 
IL29) IFNs, and these IFNs have antiviral activity by inducing a subset of ISGs [72]. ISGs 
include some genes, which show antiviral activity or are involved in lipid metabolism, apoptosis, 
protein degradation, and inflammation [10]. IFNs are effective against HCV infection, and are 
also essential for innate immunity. 
Recently, a genome-wide association study showed that SNPs, located near IL28B, which 
encodes for IFN-λ3, are strongly associated with a virological response to IFN therapy and 
spontaneous clearance of HCV [18, 63, 74, 76, 77]. Especially in Japanese patients, rs8099917 
is closely associated with efficacy for IFN therapy; patients with the TT genotype (termed 
IL28B major) have a stronger response to IFN therapy than those with TG or GG genotypes 
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(termed IL28B minor) [76]. Even after liver resection because of HCC [32] or liver 
transplantation [16], the efficacy of therapy is associated with IL28B SNP. More recently, 
IL28B major patients were reported to express hepatic ISGs, such as ISG15 and OAS, which 
were lower than those in IL28B minor patients [13, 26]. ISG expression is also known to be 
strongly associated with the efficacy of IFN therapy [13, 26]. However, after liver resection for 
HCC, the association between hepatic ISG expression and the efficacy of therapy is still 
unclear. 
Similar to IL28B SNP, IP-10 expression is a predictor for IFN therapy, and high IP-10 
expression is a predictive factor for a poor IFN response [39, 64]. Unlike other ISGs, serum 
IP-10 protein levels have been reported to be associated with differences in IL28B SNP [15, 40] 
and they also have been found not to be associated with differences in IL28B SNP [8]. IP-10 is 
one of the ISGs and it is regulated by inflammatory cytokines, such as TNF-α, via NF-κB 
transcription factor [54]. TNF-α is elevated in severe fibrosis patients [2]; therefore, IP-10 
expression should be elevated in response to progression of liver fibrosis. 
To clarify why IP-10 expression is not correlated with IL28B SNP, I genotyped IL28B 
SNP and quantitated the hepatic ISGs. I then analyzed their association, focusing on the 
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progression of liver fibrosis. I found that IP-10 expression is associated with IL28B SNPs only 
in patients with mild or no fibrosis. 
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2-3. Materials and Methods 
Human tissue samples 
Noncancerous tissue samples from 74 patients who were negative for hepatitis B virus and 
human immunodeficiency virus, were positive for HCV-RNA, and had undergone liver 
resection for hepatocellular carcinoma at the Department of Surgery and Science at Kyushu 
University Hospital between February 2004 and September 2010 were analyzed by genotyping, 
real-time RT-PCR, and immunohistochemistry. I retrospectively analyzed hepatic gene 
expression in these patients. For the non-B, non-C (NBNC) hepatitis group, I analyzed 
noncancerous tissue samples from 20 patients who were negative for hepatitis B virus, HCV, 
and human immunodeficiency virus, and had undergone liver resection for hepatocellular 
carcinoma at my institute. Samples were collected immediately after resection, as previously 
described [79], transported in liquid nitrogen, and stored at -80°C. The degree of chronic 
hepatitis in noncancerous regions was classified as follows. The degree of necroinflammatory 
activity (grading) was graded from A0 to A3, and the degree of fibrosis (staging) was staged as 
F0 to F4. Histological diagnosis of the noncancerous tissues was based on the General Rules for 
the Clinical and Pathological Study Group of Japan [28]. The study protocol conformed to the 
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ethical guidelines of the 1975 Declaration of Helsinki, and patient samples were collected after 
obtaining informed consent, according to an established protocol approved by the Ethics 
Committee of Kyushu University. The data do not contain any information that could lead to the 
identification of the patients. 
 
IL28B genotyping 
DNA was extracted from the patients’ resected liver tissue, and genotyping was performed 
using Taqman GTXpress Master Mix (Life Technologies Inc., Tokyo, Japan), according to the 
manufacturer’s protocol. The Custom TaqMan SNP Genotyping Assay (Life Technologies) was 
used for identifying IL28B genetic polymorphism (rs8099917).  
 
Measurement of ISGs using real-time RT-PCR 
Total RNA was extracted from resected liver tissue using reagents for RNA extraction, 
including ISOGEN and Ethachinmate (Nippon Gene). The synthesis of first-strand cDNA was 
performed using the SuperScript III First-Strand synthesis system for qRT-PCR (Life 
Technologies) according to the manufacturer’s protocol. Real-time RT-PCR was performed 
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using the QuantiFast SYBR Green PCR kit (Qiagen). β-actin expression was used as the 
endogenous reference for each sample. The shown value was normalized using cDNA of the 
HCV replicon harboring HuH-7 cells, for an internal reference. Primers for each gene were 
designed as follows: ISG15, 5’-AGC GAA CTC ATC TTT GCC AGT ACA-3’ (sense) and 
5’-CAG CTC TGA CAC CGA CAT GGA-3’ (antisense); OAS, 5’-GGG TGG AGT TCG ATG 
TGC TG-3’ (sense) and 5’-GGG TTA GGT TTA TAG CCG CCA G-3’ (antisense); IP-10, 
5’-CTG AAT CCA GAA TCG AAG GCC ATC-3’ (sense) and 5’-TGT AGG GAA GTG ATG 
GGA GAG G-3’ (antisense); TNF, 5’-CCC AGG GAC CTC TCT CTA ATC A-3’ (sense) and 
5’-GCT ACA GGC TTG TCA CTC GG-3’ (antisense); and β-actin, 5’-CTG GCA CCA CAC 
CTT CTA CAA TG-3’ (sense) and 5’-GGC GTA CAG GGA TAG CAC AGG-3’ (antisense). 
 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded, 3-µm sections were deparaffinized in xylene, 
rehydrated through graded ethanol, and rinsed in phosphate-buffered saline. Heat-induced 
epitope retrieval was performed in 10 mM citrate buffer, pH 6.0, in a 650-Watt microwave oven 
at 80% output for 15 min. Endogenous peroxidase activity was blocked by incubation with 
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0.3% H2O2 for 10 min. Nonspecific antibody binding was blocked by incubating the sections 
with normal rabbit serum (Dako, Glostrup, Denmark) for 10 min. The sections were then 
incubated with anti-CXCL10 goat polyclonal antibody (1:40, R & D Systems) overnight at 4°C 
and labeled with the Envision Detection System (Dako) for 1 h at room temperature. The 
sections were then developed with 3,3’ -diaminobenzidine tetrahydrochloride (DAB plus; 
Dako) and counterstained with 10% Mayer’s acid hemalum, dehydrated, and mounted.  
 
Cell culture and reagents 
HuH-7 cells were cultured in DMEM (Life Technologies) supplemented with 10% FBS 
(HyClone). The HCV replicon cells were cultured in 0.5 mg/mL G418-containing DMEM 
supplemented with 10% FBS. The replicon construct was derived from 
pFK-I377neo/NS3-3’/WT, as previously described [35]. Recombinant human IFN-α2a was a 
kind gift from F. Hoffmann-La Roche. Recombinant human IFN-λ3 and TNF-α were purchased 
from R & D Systems. ISG expression in HuH-7 and HCV replicon cells was measured using 
total RNA that was extracted from cells cultured in the presence of 100 IU/mL IFN-α, 100 
ng/mL IFN-λ3, or 1 ng/mL TNF-α for 24 h. Complementary DNA synthesis and real-time 
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RT-PCR reactions were performed as described above. 
 
Statistical analysis 
Pearson’s χ2 test was performed for qualitative variables. One-way analysis of variance 
(ANOVA), the F-test, and Student’s and Welch’s t-tests were performed for quantitative 
variables. 
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2-4. Results 
Patient characteristics, genotyping for IL28B (rs8099917) polymorphisms, and 
quantification of ISG expression 
Table 7 shows the patients’ characteristics according to the IL28B genotype. Fifty patients 
were identified as having major alleles (rs8099917 TT; IL28B major). The remaining 24 
patients had minor alleles (rs8099917 TG or GG; IL28B minor), and 2 of 24 patients had a 
minor homozygote (rs8099917 GG). I measured hepatic IP-10, ISG15, and OAS mRNA using 
noncancerous liver tissue, and found that ISG15 and OAS mRNA was significantly higher in 
IL28B minor patients than that in IL28B major patients (Fig. 24; ISG15, p < 0.005; OAS, p < 
0.005). In contrast, IP-10 expression in major patients was similar to that in minor patients (Fig. 
24; p = 0.44). Thirty-one out of 74 patients received IFN therapy prior to liver resection, and 
could not achieve an SVR. Table 8 shows patient characteristics according to receiving or not 
receiving IFN therapy. 
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Table 7. Patient characteristics and IL28B genotype. 
Factor 
IL28B SNP major 
(n=50) 
IL28B SNP minor 
(n=24) 
p value 
(univariate) 
Sex, male/female 42/8 17/7 0.187 
Age (years), mean ± SD 70 ± 8 70 ± 8 0.980 
BMI (kg/m2), mean ± SD 22.5 ± 3.3 22.0 ± 2.5 0.596 
ALT (IU/L), mean ± SD 61.0 ± 41.5 61.0 ± 49.1 1.000 
γ-GTP (IU/L), mean ± SD 72.2 ± 89.6 77.3 ± 59.5 0.774 
Cholesterol (mg/dL), mean ± SD 156.8 ± 25.0 154.3 ± 26.8 0.698 
Hemoglobin (g/dL), mean ± SD 13.1 ± 1.6 12.7 ± 1.9 0.311 
Platelet count (x 104/ mL), mean ± SD 14.1 ± 4.1 13.6 ± 5.0 0.651 
Fibrosis stage, F0/1/2/3/4 3/8/12/17/10 1/6/4/2/11 0.107 
Activity grade, A0/1/2/3 1/13/24/12 0/5/14/5 0.900 
Differentiation of hepatic cancer, 
(well/moderate/poor) 
6/35/9 4/14/6 0.611 
Tumor factor, T1/T2/T3/T4 7/26/15/2 6/12/5/1 0.652 
HCV genotype, 1/2/unknown 38/8/4 16/4/4 0.516 
HCV viral load (log IU/mL), mean ± SD 6.0 ± 1.1 6.1 ± 0.7 0.667 
 
BMI, body mass index; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase. 
Fibrosis stage and activity grade were classified according to the New Inuyama Classification. 
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Table 8. Patient characteristics and IFN therapy prior to liver resection. 
Factor 
IFN naïve 
(n=43) 
IFN experienced 
(n=31) 
p value 
(univariate) 
Sex, male/female 35/8 24/7 0.675 
Age (years), mean ± SD 71 ± 8 68 ± 7 0.153 
IL28B SNP (major/minor) 31/12 19/12 0.327 
IP-10 relative expression,  
mean ± SD 
2.2 ± 2.3 2.0 ± 1.5 0.675 
ISG15 relative expression,  
mean ± SD 
1.4 ± 1.3 1.4 ± 1.5 0.953 
OAS relative expression, 
mean ± SD 
2.6 ± 0.5 2.6 ± 0.6 0.976 
Fibrosis stage, F0/1/2/3/4 3/8/9/12/11 1/6/7/7/10 0.913 
Activity grade, A0/1/2/3 1/7/24/11 0/11/14/6 0.245 
Patient characteristics according to receiving or not receiving IFN therapy is shown.  
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Figure 24. Comparison of hepatic gene expression levels between IL28B major and IL28B 
minor patients.  
Expression levels of IP-10, ISG15 and OAS are shown. The p values were determined by 
Welch’s t-test. 
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IP-10 expression and progression of liver fibrosis 
To clarify why IP-10 is highly expressed, even in IL28B major patients, I evaluated the 
association between ISG expression and the stage of fibrosis. I found that IP-10 expression was 
significantly higher in F2/3/4 patients than that in F0/1 patients (Fig. 25; p = 0.005). I also 
separately analyzed the IL28B major and minor groups for the association between ISG 
expression and the stage of fibrosis. In IL28B major patients, IP-10 expression was significantly 
increased as the stage of fibrosis worsened (Fig. 26) (one-way ANOVA, p = 0.03). The one-way 
ANOVA analysis revealed no significant association, but tendency between other ISGs and the 
stage of fibrosis (ISG15, p = 0.10; OAS, p = 0.09). There were not enough IL28B minor 
patients for statistical analysis, but ISG expression was similar between mild and severe fibrosis 
patients (Fig. 26). To assess whether IP-10 expression was induced by progression of fibrosis 
without viral infection, I measured IP-10 expression in the liver of HCC patients with NBNC 
hepatitis. Progression of liver fibrosis did not induce IP-10 expression in the NBNC patients 
(Fig. 27a; p = 0.32). HCV infection induced IP-10 expression more strongly than NBNC 
hepatitis (Fig. 27b; p < 0.001). Immunohistochemistry using an anti-IP-10 antibody showed that 
liver sections with mild fibrosis were slightly stained. In contrast, a lot of hepatocytes were 
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stained in liver sections with more severe fibrosis compared with those with mild fibrosis (Fig. 
28). IP-10 expression in the liver was induced by progression of fibrosis, specifically in HCV 
infectious patients. 
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Figure 25 Comparison of hepatic IP-10 expression levels between F0/1 and F2/3/4 patients. 
Expression level of IP-10 in chronic hepatitis C patients. The p values were determined by 
Welch’s t-test. Bars indicate the median of these values. 
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Figure 26. Comparison of hepatic ISG expression in the indicated fibrosis patients with 
IL28B major polymorphism (upper graphs) and IL28B minor polymorphism (lower 
graphs). 
Bars indicate the median of these values. 
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Figure 27. Comparison of hepatic IP-10 expression levels with different causes of hepatitis.  
(a) Expression level of IP-10 in NBNC hepatitis patients. (b) Comparison of IP-10 expression 
levels in patients with different causes of hepatitis: HCV, alcohol, and others. Bars indicate the 
median of these values. The p values were determined by Welch’s t-test. 
  
IP-10 expression
HC
V
Alc
oh
ol
Un
kn
ow
n
0
2
4
6
13
14
NBNC (HBcAB-)
Mi
ld
Se
ve
re
0.0
0.2
0.4
0.6
n.s. 
p = 0.32
F0/1  
(n=10)
F2/3/4  
(n=10)
0
0.2
0.4
0.6
b
HCV 
(n=74)
Alcohol 
(n=5)
Other 
(n=15)
a
p < 0.001
n.s. 
p = 0.17
0
2
4
6
13
14
Fibrosis stage
IP
-1
0 
re
la
tiv
e 
ex
pr
es
si
on

 91 
 
 
 
Figure 28. Comparison of hepatic IP-10 protein expression.  
Hepatic IP-10 protein expression determined by immunohistochemistry is shown. Stained tissue 
sections from patients with differential fibrosis are shown. Arrows indicate IP-10-positive cells. 
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IP-10 expression and IL28B polymorphisms in mild fibrosis patients 
As shown in Fig. 26, IP-10 expression was increased in the F2/3/4 stage liver compared 
with that in F0/1 stage liver of IL28B major patients. Therefore, to exclude an effect of 
progression of fibrosis on IP-10 expression, I compared IP-10 expression in IL28B SNP major 
and minor patients, in those with only mild or no fibrosis. In the F0/1 patients, IL28B minor 
patients had significantly higher IP-10 expression than IL28B major patients (Fig. 29a; p = 
0.02), similar to ISG15 expression (Fig. 29a; p = 0.005). In the F2/3/4 patients, ISG15 
expression in IL28B minor patients was significantly higher than that in IL28B major patients 
(Fig. 29b; p = 0.03), while IP-10 expression was not different between these patients (Fig. 29b; 
p = 0.66).  
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Figure 29. Comparison of hepatic IP-10 and ISG15 expression between IL28B major and 
IL28B minor patients in subgroups of mild or no fibrosis (a) and more progressed fibrosis 
(b).  
Bars indicate the median of these values. The p values were determined by Welch’s t-test. 
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Inflammatory cytokine TNF-α induces IP-10 expression in HCV RNA-replicating HuH-7 
cells 
I analyzed hepatic TNF mRNA expression and its association with the stage of fibrosis. 
TNF expression was significantly higher in F2/3/4 patients than in F0/1 patients (Fig. 30, p = 
0.02), like IP-10 expression. IP-10 expression in the liver was mainly induced in parenchymal 
cells (Fig. 28). Therefore, hepatoma cell line, HuH-7 cells, and the HCV subgenomic replicon 
harboring HuH-7 cells were incubated with IFNs or TNF-α, to confirm the capability of IP-10 
induction by these stimulators. I observed that TNF-α induced IP-10 expression much higher 
than type I and III IFN (Fig. 31a). ISG15 expression was also measured in the IFN- or 
TNF-α-treated cells. I found that ISG15 was induced by IFNs, but not by TNF-α (Fig. 31b). 
These results indicate that IP-10 and ISG15 expressions are separately regulated in the liver 
with severe fibrosis. Therefore, IP-10 expression could be used as the representative of hepatic 
ISGs in patients with mild or no fibrosis. However, IP-10 expression cannot be used in patients 
with severe fibrosis. 
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Figure 30. Comparison of hepatic TNF expression levels between F0/1 and F2/3/4 patients. 
Bars indicate the median of these values. The p values were determined by Welch’s t-test. 
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Figure 31. IP-10 (a) and ISG15 (b) expression levels were measured using real-time 
RT-PCR.  
The values shown are the mean fold change induction compared with the mRNA level of 
human β-actin and the fold change induction compared with untreated cells. 
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2-5. Discussion 
In the present study, I showed that after liver resection, ISG expression was associated with 
IL28B polymorphisms. IP-10 expression was significantly associated with IL28B 
polymorphisms in patients with mild or no fibrosis, and it was affected by the progression of 
fibrosis more strongly than the polymorphisms.  
HCV-induced HCC occurs among patients with cirrhosis or bridging fibrosis. However, all 
the patients in my study were only HCC resectable patients, and therefore, patients with mild 
fibrosis would be selected, and the stage of fibrosis was widely distributed (Table 7). Hepatic 
ISG15 and OAS expressions were higher in IL28B SNP minor patients than those in IL28B 
SNP major patients, as previously reported [13, 26]. However, IP-10 expression was not 
associated with IL28B SNP (Fig. 24). Suppression of IP-10 expression during IFN therapy was 
reported [64], and some patients received IFN therapy prior to liver resection. The patients who 
had received IFN therapy prior to the resection had HCC resected at least 4 weeks after 
interrupting the therapy, and therefore, IP-10 expression was similar between patients who 
experienced IFN therapy and naïve patients (Table 8). I found that IP-10 expression was 
significantly higher in patients with progressed fibrosis than in those with mild or no fibrosis 
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(Figs. 25 and 28). IP-10 induction by progression of fibrosis complicates the association 
between IP-10 expression and IL28B SNP. In fact, in mild fibrosis patients, IP-10 expression 
was significantly higher in IL28B SNP minor patients than that in IL28B SNP major patients. 
However, in progressed fibrosis patients, IP-10 expression was similar among the patient groups 
who possessed different SNPs (Fig. 29a and b).  
In chronic hepatitis C patients, TNF-α expression is elevated with progression of liver 
fibrosis [2]. Immunohistochemistry showed that IP-10 expression was mainly induced in 
hepatocytes (Fig. 28), and only a few inflammatory cells were stained (data not shown). 
Therefore, I evaluated the effect of TNF-α and IFNs on ISG15 and IP-10 expression in the 
human hepatoma cell line HuH-7 and HuH-7-derived HCV replicon cells (Fig. 31). TGF-β is 
also fibrosis-related cytokine, however, TGF-β did not induce IP-10 expression in the HuH-7 
cells (data not shown). I found that TNF-α induced IP-10 expression is stronger than IFN 
signaling in these cells. These results suggest that even in the liver of IL28B SNP major and 
progressed fibrosis patients, TNF-α or other fibrosis-related stimulator can induce IP-10 
expression. In the liver of mild fibrosis patients with IL28B minor genotype, some IL28B 
SNP-related stimulator would induce IP-10 expression. Thus, IP-10 expression was associated 
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with IL28B SNP only in patients with mild or no fibrosis. In contrast, ISG15 was not induced 
by TNF-α, suggesting that ISG15 is strongly regulated by IFNs (Fig. 31b). Therefore, 
irrespective of progression of fibrosis, ISG15 expression is higher in IL28B SNP minor patients 
than that in IL28B SNP major patients (Fig. 29).  
In the NBNC patients, IP-10 expression was rarely induced by progression of fibrosis and 
was much lower than that in HCV infectious patients (Fig. 27b). It is reported that patients 
infected with HCV infected patients, rather than HBV, expressed higher IP-10 [2, 56]. At least 
in clinical, IP-10 induction would dramatically occur by HCV infection, and may be quiescent 
without any viral infection. Thus, IP-10 expression in the NBNC patients could be scarcely 
induced, or be near the detection limit. With TNF-α stimulation, HCV replicon cells expressed 
IP-10 mRNA more strongly than HCV RNA negative HuH-7 cells. These data suggest that 
IP-10 induction by fibrosis-related stimulation could be enhanced by HCV infection or 
replication. Recently, Thomas et al. showed that HCV infection induces IFN-λ expression in the 
liver of chimpanzees [78]. IFN-λ and fibrosis-related stimulations could induce IP-10 
expression coordinately.  
I then evaluated whether IP-10 expression can predicte therapeutic outcomes. IL28B SNP 
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is associated with IFN therapy outcomes, especially among 54 HCV genotype 1 infected 
patients. Thirty-six patients did not received IFN therapy; 19 patients due to low platelet counts, 
11 patients, due to tumor recurrence, and 6 patients rejected the therapy. Eighteen patients with 
genotype 1 infection were administered PEG-IFN-α2b and RBV combination therapy for 48 
weeks after liver resection. IL28B SNP was significantly associated with IFN therapeutic 
outcome, and the hepatic mRNA expressions of ISG15 and OAS at resection were significantly 
lower in the SVR group than those in the non-SVR group (data not shown). However, IP-10 
expression was not associated with the outcome. Lagging et al. [40] and Fattovich et al. [15] 
reported that serum IP-10 protein levels are higher in IL28B SNP minor patients than those in 
IL28B SNP major patients. Liver fibrosis of the patients in their study was less severe than that 
in the patients in my study. A correlation between hepatic IP-10 expression and serum IP-10 
protein levels was reported by Askarieh et al. [1], and hepatic and serum IP-10 expression has 
been reported as a predictor of IFN therapy outcome [39, 64]. However, IP-10 expression as a 
predictor of outcome would not be beneficial in patients with severe fibrosis. Therefore, to 
predict efficacy using IP-10 expression, progression of fibrosis should be considered. 
The mechanism of how IL28B SNP minor patients express excessive ISGs is unclear. 
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Excessive and probably maximal ISG expression before treatment would prevent the activity of 
IFN. Sugiyama et al. showed that long TA repeats in the promoter region of IL28B possess 
strong IL28B induction capability [73]. While, Smith et al. reported that IL28B polymorphism 
affects methylation in the transcription factor binding sites and results in high IL28B expression 
in IL28B SNP minor patients [70]. IL28B and IFN-λ3 have antiviral activity, and PEG-IFN-λ 
has been previously used in a clinical trial [52]. However, an association between PEG-IFN-λ 
efficacy and IL28B SNP has not been reported. Investigation of PEG-IFN-λ efficacy in IL28B 
SNP minor patients may help clarify the function of IFN-λ in HCV infection. Further studies are 
required to determine this issue, and this could improve the health of chronic HCV-infected 
patients. 
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General Discussion 
I identified a novel small molecule that acts like IFN by directly interacting with the type I 
IFN receptor to drive ISG expression, shown in chapter 1. RO8191, used in combination with 
direct-acting antiviral drugs, will add a new oral option against chronic hepatitis C infection. 
IFN-α and RO8191 share similar gene induction, therefore, RO8191 may cause adverse event 
similar to IFN-α. RO8191 have a potential to be administered orally, and may be easier to 
control the daily dosage than IFN-α that is administered weekly. Severe adverse events caused 
by RO8191 treatment may be avoided by controlling the dosage. 
I also found that RO8191 showed anti-HCV activity even in IFNAR1 or Tyk2 siRNA 
transfected cells, unlike IFN. These results were consistent with ISGs induction in IFNAR1 or 
Tyk2 deficient cells. In addition to antiviral effect, IFN showed an activation to immune cells 
and suppressor effect to tumor cells. To clarify whether IFNAR1 or Tyk2 contributes those 
effects by IFN, immune activation and cellular growth inhibitory effect by RO8191 is assessed. 
Further evaluations are needed to reveal novel molecular mechanism of IFN signaling. 
The association between IL28B SNP and clinical outcomes had been reported, and in 
chapter 2, I analyzed the association among IL28B SNP, IP-10 expression, other ISG expression 
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and liver fibrosis (Fig. 32), although, the mechanism underlying the association was unclear. 
Most recently, Prokunina-Olsson et al. reported that IFNL4 ss469415590 genetic polymorphism, 
TT or ΔG, is significantly associated with the IFN therapeutic outcome [61]. ss469415590 is 
located in the exon region of the IFNL4 gene, therefore, the ΔG allele leads to a translational 
frameshift. Patients with this ΔG allele in ss469415590 express a novel IFN-like antiviral 
IFNL4 gene; while, patients with a TT homozygous haplotype express an unknown gene 
without antiviral function. Prokunina-Olsson et al. also reported that IFNL4 ΔG would inhibit 
IFN-involving therapy. Most Japanese individuals who had rs8099917 risk alleles also had 
ss469415590 risk ΔG alleles [37], indicating IL28B risk allele is associated with the expression 
of functional IFNL4.  
Some ISGs, such as ISG15 and USP18, have been reported to inhibit IFN activity and help 
HCV replication [5, 6, 62, 68], and the expression of ISGs have been reported as a predictor of 
the possible response to IFN therapy. ISG15 and USP18 expression levels were also correlated 
with IFNL4 ΔG expression [37]. These ISGs’ expression levels would be induced by IFNL4, 
indicating that the rs8099917 polymorphism risk allele reflects the presence of the antiviral 
IFNL4 gene; and that ISGs’ expression levels are affected by IFNL4 expression levels. 
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Therefore, patients with the ΔG risk allele cannot respond to IFN therapy (Fig. 33). To clarify 
whether RO8191 shows an efficacy to the patients with IL28B/IFNL4 risk allele, evaluation of 
RO8191 using the cells that expresses high inhibitory ISGs is needed. SOCS1 is also reported as 
negative regulator of IFN signaling [3], like ISG15 and USP18. Mechanism that inhibits IFN 
signal by these inhibitory ISGs is still unclear. RO8191 activity is independent of 
IFNAR1/Tyk2, therefore, RO8191 signaling may not be inhibited by those inhibitory ISGs. 
Thus, nonresponders by current therapy may be cured by RO8191-including therapy in future.  
In conclusion, RO8191 is novel small molecule that activates IFN signaling directly, and 
RO8191 would contribute a development of novel treatment to various diseases, including 
chronic hepatitis C patients with IL28B/IFNL4 unfavorable genotype. 
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Figure 32. A schematic summary of the results reported in chapter 2. 
The association among IL28B SNP, IP-10 expression, other ISG expression and liver fibrosis is 
shown.   
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Figure 33. A schematic showing the possible mechanism of IFN-α pathway inhibition in 
the liver of patients with IL28B/IFNL4 minor SNP. 
Hepatic ISGs’ expressions in the chronic HCV infection are induced by IFNL4, indicating that 
the rs8099917 polymorphism risk allele reflects the presence of the antiviral IFNL4 gene. 
Patients with the IL28B risk allele cannot respond to IFN therapy due to high expression of 
inhibitory ISGs.   
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